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Osteoarthritis is the degradation of the knee cartilage within the joints that is often 
painful and can be debilitating and affect movement, thus impacting the overall 
quality of life. Current approved treatment methods include microfracture, autologous 
chondrocyte implantation (ACI) and osteochondral autograft transfer system (OATS). 
Tissue engineering approaches that are still under clinical trials include naturally 
derived or synthetic biocompatible scaffolds that possess good mechanical properties, 
or minimally manipulated devices like decellularized juvenile cartilage that are yet to 
demonstrate long-term benefits. Using the therapeutic potential of undifferentiated 
stem cells not only provides a sustainable and long-term approach but also promotes 
natural healing of the damages cartilage through biochemical cues. The current thesis 
work describes the evaluation of 3D stem cell aggregates for the regeneration of the 
osteochondral interface to overcome some of the limitations posed by the above 
surgical techniques. In vitro and in vivo studies were completed to evaluate the 
performance of aggregates in both a hydrogel system and a rat in vivo system. 
Compared to conventional cell suspensions, aggregates had improved cellular 
response, biochemical content and higher chondroinductive gene expression. 
Furthermore, the chondrogenic nature of the aggregate was next investigated as a 
consequence of cellular media priming and substrate coating. Specifically, ‘raw 
materials’ such as chondroitin sulfate and aggrecan in the culture medium 
outperformed growth factors in chondroinductive gene expression and collagen 
production, thus producing chondromimetic cellular aggregates. In vivo studies 
 iv 
demonstrated the feasibility and efficacy of cellular aggregate technology with two 
different cell densities and combining them with fibrin at the defect site. In the 
Sprague-Dawley rat knee, implants with higher cell density aggregates received 
higher morphology scores, better immunohistochemistry staining, and demonstrated 
the best defect filling compared to the fibrin-alone group. Moreover, this thesis has 
taken the cell-aggregate technology from an in vitro proof of concept study to a 
translational in vivo animal model, thus opening new avenues of investigation for 
further refinement of the technology. The important next steps will be to characterize 
the mechanical properties of the scaffolds in an in vivo model, and further explore the 
regenerative-potential of the stem cell aggregates in a large animal model. 
 v 
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CHAPTER 1: Introduction 
 
The overall objective of my dissertation was to introduce and evaluate the cartilage 
regenerative potential of three dimensional mesenchymal stem cell aggregates. The overall plan 
was to start with a completely material-only approach, transition to hydrogel encapsulated cell 
aggregates that are further refined, and to finally test the aggregates with fibrin alone in a rat 
knee defect model. To look at both material-based strategies and also perform an in-depth 
analysis of the stem cell aggregates, the thesis design included three corresponding aims:                         
(1) characterization of acellular microsphere-based scaffolds with raw materials encapsulated (2) 
biofabrication and in vitro analyses of stem cell aggregates encapsulated in hydrogels, further 
refined by media priming and substrate stiffness (3) preliminary in vivo testing of two different 
cell density aggregates in a rat trochlear knee defect model. 
 The first aim was to characterize the degradation of raw material encapsulated 
microsphere-based scaffolds fabricated by a well-established technology from the research 
group. The second aim was to develop a platform technology to fabricate stem cell aggregates 
from different cell sources, rat bone marrow mesenchymal stem cells (rBMSC) and human 
umbilical cord Wharton’s Jelly cells (hWJC), encapsulate the aggregates in an agarose hydrogel 
model and test the chondrogenic properties over a period of three weeks. The second part of 
second aim was to further refine the aggregates alone by testing the chondroinductive properties 
of the rBMSC aggregates that are grown under different media formulation (growth factor and 
raw materials) and substrate stiffness induced by hyaluronic-acid coated plates. The third aim 
tested the feasibility of the aggregates sealed with fibrin, when implanted in a rat trochlear 






Chapter 2 provides a background on the current commercialization environment for 
cartilage tissue engineered products in the United States. This chapter covers the different 
treatment options, specific examples of devices, biologics, and injectable drugs and associated 
federal regulations. It provides a brief overview of animal models for cartilage regeneration and 
other considerations to keep in mind for establishment of clinical studies. The knowledge gained 
from Chapter 2 inspired the pursuit of both material-based (microsphere scaffolds) and cell-
based (stem cell aggregates) approaches toward a common goal of osteochondral tissue 
engineering. 
Chapter 3 addresses the first aim, i.e., the characterization of acellular homogenous raw 
material encapsulated microsphere-based scaffolds. Two different types of PLGA were 
encapsulated with chondroitin sulfate (CS) and β-tricalcium phosphate (TCP) and the scaffolds 
were characterized for dry weight, molecular weight, CS and TCP retention in scaffolds, and 
mechanical properties, over a period of four weeks. The results of this study provided insight 
into degradation properties of raw-material encapsulated scaffolds that can use utilized in the 
study design for future in vivo experiments. 
Chapter 4 addresses the second aim by introducing the first full-scale study in which the 
cellular aggregates were fabricated from two different cell sources (rBMSCs and hWJCs). 
Secondly, the aggregates were encapsulated in a 3% agarose hydrogel system with different 
aggregates per scaffold and different cell density/aggregate and were compared to conventional 
cell suspension group. Testing parameters included cell viability, biochemical assays, gene 
expression and immunohistochemistry. The high cell density aggregates outperformed the cell 
suspension groups in terms of aggrecan gene expression and GAG production, thus providing 






The results from this study established a platform technology for aggregate fabrication and 
encouraged the idea behind the successive studies. 
Chapter 5 further addresses the second aim with an objective to generate chondromimetic 
rBMSC cell spheroids that are cultured on surfaces with different stiffness and primed under 
varied media compositions for a period of one week. Cell viability, biochemical assays, gene 
expression, and immunohistochemistry data was evaluated as a function of aggregates under 
different growth factor and raw material-composed media and under different surface stiffness.  
Chapter 6 addresses the third and final aim of evaluating the rBMSC aggregates in a rat 
in vivo model. Critical sized defects were created in the trochlear groove of Sprague-Dawley rats 
and implanted with aggregates of two different cell densities evaluated for a period of 8 weeks. 
After sacrificing the animal at 8 weeks, immunohistochemistry was performed to assess cartilage 
tissue regeneration.  
Chapter 7 serves as a summary of my thesis work, and highlights common trends 
observed from the different projects. Recommendations for future experiments and studies are 
made based on informed observations from conducted studies. The work within this thesis 
proposes a novel approach for treating focal cartilage lesions, by means of presenting cells in a 
three-dimensional aggregate manner. Currently, autologous chondrocyte implantation (ACI) is 
the only FDA-approved cell-based therapy in the Unites States. Although there are several new 
upcoming approaches widely discussed in Chapter 2, the major limitations are multiple surgeries 
and the time taken from diagnosis to treatment. Utilizing allogeneic cellular aggregates is an 
attractive solution that addresses donor site morbidity and presents a readymade solution without 






















Despite numerous efforts in cartilage regeneration, few products see the light of clinical 
translation, as the commercialization process is opaque, financially demanding, and require 
collaboration with people of varied skill sets. The aim of this review is to introduce, to an 
academic audience, the different paradigms involved in the commercialization of cartilage 
regeneration technology, elucidate the different hurdles associated with the use of cells and 
materials in developing new technologies, discuss potential commercialization strategies, and 
inform the reader about the current trends observed in both the clinical and laboratory setting for 
establishing clinical trials. Although there are review articles on articular cartilage tissue 
engineering, independent reports provided by the Food and Drug Administration (FDA), and 
separate review articles on animal models, this is the first review that encompasses all of these 
facets and is presented in a format favorable to the academic investigator interested in clinical 
translation from bench to bedside. 
 
                                                 
1
 In Press as Sridharan B, Sharma B, Detamore MS, “A roadmap to commercialization of cartilage therapy in the 








Cartilage defects of the knee range from cartilage lesions and osteochondritis dissecans to 
debilitating grade III or IV osteoarthritis (OA; see Table 2.1 for listing of abbreviations), and 
result in more than 200,000 surgical procedures annually
23, 50, 162
. Current surgical treatment 
paradigms range from microfracture for initial impact injuries to total knee replacement in 
advanced cases; however, there are no universally agreed-upon solutions that have unequivocally 
been shown to regenerate fully structural and functional cartilage
28, 96, 204, 212, 233
. Specialized 
surgical treatments, such as autologous chondrocyte implantation (ACI), have emerged over the 
past few decades and have often been used among younger patients. However, ACI has not been 
as successful for long-term treatment of older patients
53, 200
. Microfracture is the established 
standard of care for focal cartilage defect repair and is commonly used as a comparator group in 
clinical trials with devices and autologous grafts.
90, 268
 Academic tissue engineering solutions 
endeavoring to restore and repair cartilage have traditionally used the triad approach (cells, 
biomaterials, and bioactive factors) with common materials such as polycaprolactone (PCL), 
poly(ethylene glycol) (PEG)-based materials, poly(lactic-co-glycolic acid) (PLGA), agarose, 
chitosan, collagen, and hyaluronic acid, which have all been employed in other products that 
have been FDA approved.
36, 89, 148
 Different sources of cells, such as chondrocytes, bone marrow 
mesenchymal stem cells, adipose-derived stem cells, and cells derived from the umbilical cord 
have been employed in efforts to differentiate these cells toward a chondrocyte-like phenotype 
using polymeric substrate adherence, novel cell culture media, growth factors, and/or gene 
therapy.
92, 103, 199, 206
 Over the years, biomaterials strategies have evolved from a single polymeric 
substrate to superior hierarchical matrices that mimic the native tissue and attempt to enable 
directed differentiation
222
. Recently, ‘raw materials’
209










) and demineralized bone matrix (DBM) have been used 
directly or combined with other biomaterials to create hybrid materials that provide biochemical 
and mechanical cues for the cells to differentiate.
224, 241, 245
 Some of the current products that 
employ this technology are DeNovo NT from Zimmer
77, 78
 and DeNovo® ET (Engineered Tissue 
Graft) from ISTO technologies, which obtained special rights and permission from Zimmer
107, 
247
. Both products employ juvenile decellularized cartilage with a combination of cells and 
materials to treat cartilage lesions. BioCartilage from Arthrex
1
 employs micronized allogeneic 
cartilage to treat osteochondral lesions. 
 
Despite so many new innovative approaches and technologies that address articular cartilage 
regeneration, there are very few FDA approved products and only a handful of products 
currently in clinical trials
155
 (Tables 2.2, 2.3, and 2.4). Unfortunately, academic training does not 
typically provide a clear picture of the various steps involved in therapeutic product design, 
development, registration, and launch
39
. A thorough understanding of the challenges in 
translation, restrictions due to government regulations, funding opportunities, and overall study 
design is of paramount importance to help academics think about product development while 
designing hypothesis-driven research, proposing innovative and novel strategies, designing 
animal studies with the final clinical study in mind, and understanding the cost-benefit ratio in 
every step of the process to enable a smoother transition from pre-clinical animal studies to 
human clinical studies. Review papers have done an excellent job in covering various facets of 





osteochondral scaffolds for cartilage tissue engineering
39, 196, 201, 223, 250
 challenges of stem cell 
technology,
53, 121, 123, 199
 product legislation in other countries,
205







20, 58, 84, 87, 144, 263
 However, the current review endeavors to 
classify the different categories of tissue-engineered products and their relative benefits and 
challenges associated with specific product examples. Secondly, we also discuss different animal 
models, inclusion and exclusion criteria for clinical studies, primary and secondary endpoint 
analyses, and a standard set of FDA recommendations. Thirdly, we aim to give the reader a brief 
introduction into other commercialization considerations to keep in mind before launching into 
translation. Finally, the current review aims to introduce a product development-based 
perspective to the academic investigator in anticipation of future healthcare commercialization. 
Therefore, building on other outstanding reviews, the current review fills a gap in the literature to 
provide a roadmap to commercialization for academic investigators to translate their cartilage 
regeneration technologies.  
 
METHODS 
A review of all of the tissue engineered and industrial products, inclusion and exclusion criteria, 
and FDA approval status was performed using clinicaltrials.gov with the search terms “articular 
cartilage” and “osteoarthritis” in March 2015 to determine the current status of active clinical 
trials for cartilage repair treatments. Additionally, the corresponding company’s website was also 
reviewed for additional product information. FDA guidance documents, clinical trial 
recommendations by the International Cartilage Repair Society (ICRS), and large animal study 








Three common surgical procedures are utilized to address OA or cartilage degeneration. The first 
procedure, microfracture, is a marrow stimulation technique, whereby a full thickness chondral 
defect is created, including removal of calcified cartilage, followed by puncturing the underlying 
subchondral bone with a drill or awl to create small holes for bone marrow constituents, 
including MSCs, to fill the defect.
8, 118
 The resulting tissue is less durable, less organized, and 
has a higher quantity of collagen type I than normal articular cartilage.
192
 Poor clinical outcomes 
from microfracture have been associated with inadequate filling of defect with repair tissue and 
osseous overgrowth.
29, 176
 Good outcomes are typically limited to young patients (<40 years with 
small lesions (<2 cm
2
), low body mass indexes, and acute onset of symptoms.
178
 Otherwise, 
clinical results are highly variable. Approaches to improve the repair process initiated by 
microfracture are being actively explored. BioCartilage from Arthrex (Naples, FL), employed 
frequently with platelet rich plasma (PRP),
1
 and another approach by Milano et al. from Catholic 
University (Rome)
173
 have both employed microfracture in combination with their scaffold and 
are comparing that with a scaffold-only approach (i.e., without microfracture) to evaluate the 
complementary effect of microfracture. The final data from the BioCartilage study are expected 
to be available in June 2016. The importance of microfracture as an emerging comparator group 
in clinical studies will be discussed in the next section.  
 
The second procedure is mosaicplasty, or osteochondral autograft transfer, which involves 
surgical transfer of mature autologous or cadaveric tissue from a non-load-bearing region to a 
cartilage defect.
104, 248
 While this relatively inexpensive reparative technique has helped to serve 












 with time, patients seem to develop symptoms attributable 
to the donor area, thus reducing the overall effectiveness of this technique.
105
 In addition to 
donor-site morbidity, the technically challenging autologous procedure adds complexity for the 
surgeon and requires longer operating times. 
 
The third and most widely used procedure is autologous chondrocyte implantation (ACI). ACI is 
a two-step procedure wherein chondrocytes are harvested arthroscopically from healthy cartilage 
and expanded in vitro before reimplantation through a second, more invasive surgery that 
requires a periosteal flap to be harvested from the patient that must be sutured to the cartilage 
surface to keep the cells in place. ACI is technically challenging, costly, requires two surgeries, 
must receive health insurance approval, and has been associated with high reoperation rates.
16, 133
 
Several modifications to ACI have been introduced. The most popular is the matrix-induced ACI 
(MACI), which involves implantation of in vitro expanded chondrocytes in a suitable matrix, 
which is then fixed in the defect area using fibrin glue and/or sutures.
91
 This does not refer to the 
Sanofi biosurgery registered MACI® product. Several papers have evaluated side-by-side 
performance of ACI, microfracture, and mosaicplasty over long periods
65, 96, 170
 and have 
produced recommendations factoring in the age and nature of cartilage injury (stage of OA and 
size of the lesion). In one study, both MF and OATS showed encouraging clinical results for 
athletes under the age of 40 with the OATS group producing slightly increased results over MF, 
assessed over a period of 37.1 months.
97
 Gudas et al.
5
 compared the effect of MF, OATS, ACI, 
and debridement in articular cartilage lesions associated with ACL injuries and a 3-year follow-
up. Pain scores revealed that intact articular cartilage during ACL reconstruction yields more 








However, if an articular defect is present, the subjective IKDC scores are significantly better for 




The choice of the comparator group is largely dictated by the regulatory requirement for the 
specific type product.  For cell-based products, ACI is the most commonly employed comparator 
group. The use of ACI as a comparator group is challenging, as it is expensive and logistically 
demanding, and, consequently, has not been widely adopted. On the other hand, microfracture is 
a more straightforward procedure and is the most commonly used first-line procedure for 
cartilage regeneration; it has therefore been a popular choice as a comparator group in clinical 
trials. However, the defect type and disease state of the joint must be considered to be within the 
clinical indication for microfracture. 
 
CHOICE OF COMPARATOR GROUP IN CLINICAL TRIALS 
Comparator groups for cartilage therapy change according to the treatment modality and include 
placebo and standard of care groups. FDA guidelines require that experimental groups 
demonstrate statistically superior primary endpoints of treatment over a current comparator 
group such as microfracture, debridement, mosaicplasty, and ACI.
166, 177
 Microfracture is the 
most commonly used comparator group for late-phase clinical trials, as it is inexpensive 
compared to ACI, easier to perform, and is widely performed throughout the world. However, 
FDA Guidance also allows ACI as a control group for large defects (greater than 5-7 cm
2
 
lesions) where microfracture may not be indicated.
177, 252
 In summary, choosing a comparator 






disease sate of the joint, results of existing or previous clinical studies, and guidance from FDA/ 
consultants. It is important to note that the recent literature suggests that, for most focal defects 
of the knee cartilage and small-sized lesions due to impact injuries, microfracture is emerging to 
be a superior comparator group in light of effective repair tissue formation and availability of 
uniform instruments with which to perform the surgery throughout the country. 
 
CURRENT TRANSLATIONAL TECHNOLOGIES IN CARTILAGE 
REPAIR 
 
The following sections will highlight the FDA classification scheme and briefly cover the 
different approaches (i.e., devices, drugs, and biologics) with current examples in clinical trials 
and, finally, provide summary of these translational technologies as well as their relative benefits 
and limitations. 
 
FDA Classification of Cartilage Repair Therapies 
 
Within the FDA, the Center for Devices and Radiological Health (CDRH), the Center for 
Biologics Evaluation and Research (CBER), and the Center for Drug Evaluation and Research 
(CDER) are responsible for devices, biologics, and drugs, respectively.
166
 The type of 
classification impacts the number of subjects enrolled, the nature of primary and secondary 
endpoints, and the implementation period to the market. The duration of a study is also impacted 
by the nature of control groups, recovery periods, long-term pain evaluation, device performance 
tracking, and post-market surveillance. Tables 2.2, 2.3, and 2.4 list all of the products either 
currently in the process of seeking FDA approval, which are classified as device, drug, biologic, 








Most of the devices, biologics, and drugs are classified under section 351 or 361 of the Public 
Health Service (PHS) Act.
44
 Scaffolds, polymeric constructs, and injectable pastes are likely to 
fall under the device classification, while stem cell technologies, combinatorial products that 
employ cells and materials, and incorporation of protein molecules like amino acids and growth 
factors are most likely going to be treated as a drug or biologic. Given that some cartilage tissue 
engineering technologies may be considered combination products, any ambiguity in 
classification can be directed to the Office of Combination Products (OCP). A company must 
submit a Request for Designation (RFD) to the FDA, which enables the FDA to determine the 
primary mode of action and to thus decide (within 60 days of RFD filing) the lead agency 
(CDRH, CBER, or CDER) for premarket review and regulation. 
 
Before using any product for clinical trials, the FDA must approve an investigational device 
exemption (IDE) for devices or an investigational new drug (IND) for drugs and biologics. It 
must be noted that CBER may also regulate some devices (e.g., cellular products), in which case 
the IDE route is followed. In addition to FDA’s IDE or IND approval, institutional review board 
(IRB) approval must be obtained prior to clinical trials, and one should expect that their IRB(s) 
would require FDA involvement before merely allowing a pilot clinical study. The clinical safety 
and efficacy data collected with IDE approval for devices are then used for either a Premarket 
Notification (510(k)) or Premarket Approval (PMA) application, which, if approved, allows the 
company to sell their device in the United States. The PMA is a longer, more complex, and more 
costly process than the 510(k). A 510(k) pathway requires that the device to be marketed is 






includes a device that was legally marketed in the US before May 28, 1976, a device that has 
cleared through the 510(k) process, or devices that have been down-classified from Class III to 
Class II or Class I. The necessary proof of safety and efficacy is determined predominantly via 
preclinical studies, though in some cases a clinical study is required.  Nearly all Class III medical 
devices, which include most cartilage repair technologies, require a PMA, which is the most 
stringent type of device marketing application required by FDA. Unlike a 510(k), a PMA 
requires clinical studies that will need to demonstrate either non-inferiority or superiority against 
a control group, the determination of which depends on risk-benefit considerations posed by the 
product. In some rare cases, evaluation against an objective performance goal or criteria, rather 
than an active control group, may be appropriate. Clinical trials for PMAs typically consist of a 
small feasibility/pilot study to determine safety, and a pivotal study to demonstrate efficacy in 
addition to safety. There are no predicate devices (Class I and II) for most cartilage repair 
products, therefore, a PMA is required to legally market them. Some devices indirectly related to 
cartilage repair may be amenable to the 510(k) pathway. In contrast to devices, clinical safety 
and efficacy data collected with IND approval for biologics and drugs then lead to either a 
Biologics License Application (BLA) (via CBER) or a New Drug Application (NDA) (via 




The CDRH is responsible for the approval of cartilage repair devices including biodegradable 
scaffolds, osteochondral plugs, and injectable substances that can fill defects. Depending on an 






determines that the primary mode of action is as a device. The two primary routes to acquire 





It is important to note that most devices for cartilage application that are currently in clinical 
trials are from non-US-based companies and/or universities. Notable among them are HYTOP® 
from TRB Chemida (Germany), Agili C Biphasic Implant from CartiHeal (EU), and BST-
CarGel from Piramal Healthcare (Canada).
78, 134, 225, 232
 
 
According to information found at clinicaltrials.gov, DePuy’s Cartilage Autograft Implantation 
System (CAIS) is a kit of devices that employs morselized autologous cartilage harvested 
arthroscopically from a non-weight-bearing region, affixed onto a synthetic resorbable implant 
using fibrin sealant, and implanted in a single surgical procedure. CAIS has just completed Phase 




HYTOP® is a two-layer bioresorbable matrix consisting of an upper layer of highly purified 
porcine splint skin and a lower layer of purified collagen fleece containing hyaluronan (HA). The 
primary working hypothesis is that HYTOP® is safe and suitable as a cell-free matrix to support 
hemostasis, as a cover for the cartilage lesion and eventually to enhance cartilage regeneration in 
a one-step surgical procedure. TRB Chemida AG, a German company that is sponsoring the 








The Agili C Biphasic Implant™ is an off-the-shelf cell-free biphasic plug and is CartiHeal’s 
trademarked product used in the treatment of focal articular cartilage and osteochondral defects. 
The biphasic implant is composed of calcium carbonate in the aragonite crystal form and 
composed of modified aragonite and hyaluronic acid in the cartilage phase. Holes are drilled into 
the bottom phase, comprised of coral material, through which the top phase material (hyaluronic 
acid) is gradually added to initially form a gradient, followed by a controlled deposition to form 
the desired height.
135
 The product has currently secured approval for use in the European Union 
market and is running a multi-center post-marketing clinical study (phase IV). As of 2015, the 
company secured four patents (three in the U.S. and one in Japan) for its proprietary cell-free, 
off-the-shelf cartilage regeneration technology for patients with injuries to the articular surface of 
joints.
134
 The product is not currently commercially available in the U.S. 
 
BST-CarGel is a Canadian Piramal Healthcare product that is prepared by mixing chitosan and a 
buffer to form a liquid-like gel that has scientific evidence for biocompatibility and adherence to 
tissue. The BST-CarGel, which is fabricated under Canada’s certified GMP protocol, is mixed 
with a patient’s own blood and implanted into the surgically prepared defect lesion site. BST-
CarGel was found to be safe and effective according to multi-center randomized controlled 
clinical trials.
210, 236
 According to the company’s website, the safety was assessed to be similar to 
that of microfracture, and results demonstrate greater quantity and quality of repair cartilage. 
 
INJECTABLE DRUGS 
According to CDER at the FDA, current cartilage treatments that fall under the “Drugs” category 








 By definition, compounds that address cartilage repair and are metabolized, are 
classified as drugs and injectable forms are also therefore considered a drug.
4
 It should be noted 
that viscosupplements, such as hyaluronic acid, are considered devices rather than drugs, since 
their primary mode of action is viscosupplementation and not cartilage repair or metabolic 
mechanisms.
260
 Approval of a drug requires a phased approach with separate dosing (phase I), 
assessment of small-scale safety and effectiveness (phase II), and assessment of large-scale 
randomized safety and effectiveness (phase III); it therefore imposes more financial and clinical 
expenditure than the device route. Most of the cases that consult drug treatment are advanced OA 
and are usually not treatable by the device or biologic paradigm due to the condition of the joint 
or other reasons. Thus in most cases, drugs represent a palliative treatment paradigm and are 
usually used to treat advanced OA. 
 
Examples of approved drugs include injectable Synvisc by Genzyme, topical NSAID cream 
Pennsaid by Nuvo Research, and other steroid-based painkillers that address inflammation, such 
as Supartz by Smith and Nephew and Mobic by Boehringer Ingelheim. A few drugs in phase III 
clinical trials include Condrosan by Bioiberica and dextrose injection by Universidad Nacional 
de Rosario. Condrosan is a prescription drug containing highly purified chondroitin 4- and 6-
sulfate of bovine origin in a concentration of not less than 98%. It has an average molecular 
weight of about 15–16 kDa, and an intrinsic viscosity of about 0.02–0.06 m
3
/kg, and it has been 
approved as a prescription treatment for OA in many European countries.
262
 Some other notable 








TPX-100: According to the company’s (OrthoTrophix) website, TPX-100 is a 23 amino acid 
peptide derived from matrix extracellular phosphoglycoprotein (MEPE) and has shown success 
in cartilage regeneration in large animal models through regulation of hard tissue and phosphate 
metabolism. TPX-100 is delivered via intra-articular injection, and has shown success in phase I 
and II trials for dentin regeneration. It is currently under randomized double blind, placebo 
controlled, multidose phase II trials for treating grade ICRS grade 3,4 bilateral OA with focal 
defects no greater than 1 cm. There have been no adverse events from previous clinical and non-
clinical studies.
128
 Specific cartilage or bone tissue regeneration, lack of ectopic bone formation, 
promotion of chondroprogenitor cells, and a long-term pharmacodynamics effect make TRX-100 




Condrosan is a hard capsule of chondroitin sulfate marketed by Bioiberica in Canada and Spain. 
Publication and clinical studies revealed that Condrosan was found to perform better than 
Celecoxib, an anti-inflammatory steroid-based pain killer drug,
202, 262
 and reduced cartilage 
volume loss and marrow lesions in the knee as early as six months after administration.
202
 
Condrosan represents a symptomatic treatment, and future long-term analysis (phase IV) will 
help to determine efficiency of pain relief for arthritic patients. 
 
AS902330 is a recombinant form of fibroblast growth factor 18 (rhFGF-18) currently in phase II 
clinical trials, sponsored by Merck KGaA from Geneva. The drug is delivered intra-articularly in 
the knees of patients with primary OA
159, 274
 and measured for safety, efficacy, and residual 






microfracture for clinically diagnosed stage I OA would be the next step in comparing drug 
treatment with standard of care. 
 
In summary, drugs vary from steroid injection to anti-inflammatory drugs to hyaluronic acid 
injections. Since these treatments are mainly pain relieving either directly or indirectly, they 
often require multiple injections and life-long treatment and can be prohibitively expensive for 
the retired and elderly population. The drug route through the FDA is typically a longer process 
to demonstrate safety and efficacy in a large cohort, often with multiple comparator groups. 
 
BIOLOGICS 
Products that use growth factors and/or extracellular matrix in conjunction with cells to repair 
defects typically fall under the biologics or combination product category according to the 
CBER.
166
 Similar to the drug criteria, biologics testing require dosing, safety and efficacy, and 
large-scale randomized safety and efficacy studies (phase I, II, and III), with each phase 
requiring an IND approval for commencement in the Unites States. After phase III, a BLA is 
submitted to the CBER for review and approval.  
 
Autologous cellular products 
Utilizing a patient’s own cells to repair osteochondral defects is achieved by an initial biopsy or 
cell isolation, in which cells are expanded in vitro and re-implanted into the defect area.
27
 
Genzyme’s Carticel, one of the pioneers that paved the way for this technology, is also FDA-
approved and has been used to treat patients since 1995, according to the company’s website.
191
 






the patient from a lesser weight-bearing, non-articulating surface and transported to Genzyme via 
a Genzyme Biopsy Cartilage Transport Kit. After about 6 weeks, the cells are transported back to 
the medical center and implantation is performed by a trained CARTICEL® surgeon. The defect 
region is prepared by damaged tissue debridement and procurement of a periosteal flap. After 
confirming homeostasis, the cells are re-suspended to the defect region via a catheter and the 
defect is covered and sutured with fibrin glue and the aforementioned periosteal flap. In general, 
ACI has favorable reports of regeneration predominantly for a younger population (up to 40 
years),
30, 109
 whereas chondroplasty and microfracture are more common and routinely 




Most cellular products under the biologics designation employ MSCs from bone marrow, 
adipose tissue, or umbilical cord with a combination of material and/or PRP and are delivered as 
a patch or injection.
98, 116
 Notable among them are adipose-derived stem cells (ASC) that are 
isolated from a patient’s own fat pad, which can be processed by medium selection and seeded 
on a collagen dermal matrix with fibrin glue. Such a study is currently recruiting participants in a 





The University of Marseille in France conducted a pilot (phase 0) study to evaluate the efficacy 
and safety of scaffolds composed of fresh non-expanded autologous bone marrow-derived 
mesenchymal mononuclear stem cells, stimulated with a protein matrix and mixed in a collagen 
hydroxyapatite scaffold. This cellular paste was then transplanted in the prepared defect 









Investigators at the University Hospital of Basel in Switzerland, in collaboration with a non-
profit organization situated in Germany called Deutsche Arthrose-Hilfe, are currently in phase I 
clinical trials conducted in Switzerland for evaluating the safety and feasibility of implanting an 
engineered cartilage graft in the femoral condyle or trochlea of the knee after a traumatic injury 
with one or two symptomatic lesion(s) of grade III, IV and a defect area between 2 and 8 cm
2
. 
The graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen 
type I/III membrane (Chondro-Gide®) into the cartilage defect on the femoral condyle and/or 
trochlea of the knee after a traumatic injury.
203
 According to clinicaltrials.gov, it was found that 
the current study was a phase I, prospective, uncontrolled, investigator-initiated clinical trial 
involving 25 patients. 
 
Allogeneic cellular products 
Allogeneic products use human donor cells and tissues to repair damaged cartilage, thereby 
reducing the need for a primary biopsy, reducing donor site morbidity, and allowing for a one-
step procedure. Allogeneic products include morselized tissue and transgenic cells engineered to 
secrete growth factors,
18, 165
 although some of the donor tissues, which are minimally 
manipulated, are regulated as an organ transplant and not as a biologic. 
 
CARTISTEM®, a product developed by Medipost Co. Ltd., has currently completed phase III 
clinical trials in the United States, and was approved for clinical use by the Korean FDA 
(KFDA). According to the company’s website, CARTISTEM® contains selectively grown 






the cartilage defect region, although it is unclear from available sources how the solution stays in 
the defect. The inclusion criteria for the study include patients with cartilage lesions between 2 
and 9 cm
2
 in area. The intervention by allogeneic treatment is being compared in clinical trials 
with microfracture. The Korean’s government approved the usage of CARTISTEM® as an off-
the-shelf, stem cell drug manufactured according to GMP standards.
261, 266
 The long-term 
efficacy of the drug treatment is the next question the company will be addressing through phase 
IV clinical trials. 
 
TG-C, sponsored by TissueGene, Inc., is currently in phase II clinical trials in the United States 
and in phase IIb in Korea. Delivered through a local injection, TG-C offers a non-invasive 
therapy that treats the symptoms and causes of osteoarthritis. Allogeneic human donor 
chondrocytes are transfected by viral vector to produce TGF-β1 and are called the modified cells. 
The product is composed of a 3:1 ratio of unmodified to modified chondrocytes, delivered as an 
intra-articular injection to patients with grade 3 chronic degenerative joint disease of the knee, 
and compared against placebo normal saline injection.
101
 Before injecting the cells, synovial 
fluid is removed from superolateral portal region of the joint and the knee is laid out straight in 
the supine position for two hours during the course of slow injection to obtain a dependent 




According to the company’s website, TissueGene’s allogeneic cells (i.e., donor cells) are mass 
cultured and mass packaged in DMEM media and are delivered in a ready-to-inject, off-the-shelf 









Revaflex, used for the treatment of ICRS Grade III and IV articular cartilage lesions of the knee, 
is marketed by ISTO Technologies, and has currently proceeded to conduct phase III clinical 
trials to evaluate safety and efficacy of the graft versus the microfracture technique.
79
 The 
engineered tissue implant consists of living cartilage tissue grown in the laboratory, cultured 
using human cartilage cells. The scaffold is surgically inserted into the subchondral bone using 
fibrin glue for patients with cartilage defects. 
 
Geographically independent companies like CARTISTEM® from Korea, Chondrogen from 
Osiris, and RepliCart from Australia have marketed products in their respective countries and are 
currently in the regulatory space for product approval in the United States. Closely following the 
companies’ clinical trials, outcome measures and learning along the way will reduce both cost 
and time for future applicants and introduce both the investigator and the FDA to a niche 
treatment modality. 
 
Compared to cell-based products, allogeneic treatments such as MSCs offer the option of tissue 
storage, commercial opportunity via tissue banking and also reduces a patient’s time in the 
hospital, thus reducing overall healthcare costs. 
 
Summary of the Cartilage Treatment Technologies 
For cartilage repair technologies, devices, drugs, and biologics are the three main pathways to 
secure US regulatory approval for licensing and marketing. On one hand, devices currently have 
yet to show long-term successful cartilage regeneration, but they have adequately been shown to 






late-term OA symptoms although many approaches are currently underway to treat early 
symptoms, and results are yet to show long-term successful treatment of osteoarthritis. Cell 
therapies present challenges for choosing animals for pre-clinical models. It is the responsibility 
of the investigators to ensure close mimicking of the human system; hence, choosing between 
allogeneic versus autologous cells becomes important. Moreover, choosing the right cellular 
phenotype, ensuring GMP standard of practice, evaluating the effect of immunosuppressants on 
overall health, and efficiency of the surgical procedure on older populations must be evaluated 
even at the pre-clinical step by using alternatives, such as older animal populations and carefully 
drafted assay procedures. Some of the major challenges of autologous cell-based techniques are 
the need for two or more surgeries in addition to production and facility expenses. Additionally, 
cost to the patient, healthcare expenses, and insurance reimbursement are major role players in 
determining the route of treatment and availability throughout the country. The principal 
investigator(s) may save a lot of time, money, and effort if pre-clinical data that are submitted to 
the FDA demonstrate durability, safety, and efficacy of the product/treatment/technique. Of 
special significance is the design of the large animal study and its clinical endpoints, as it sets the 
stage for upcoming human clinical trials. Adequate physician and surgeon training for consistent 
device delivery into the defect region and employing uniform surgical practices for a given 
device/biologic dictate the overall power as well as aid in increasing the power of the 
experimental design. 
 
ANIMAL STUDIES FOR CLINICAL TRIALS 
 
Small and Large animal study 
Several parameters to consider when choosing between small and large animals for cartilage 
repair are clearly outlined by Stannard et al.,
49
 Chu et al.,
45
 Ebihara et al.,
75








They provided extensive information and aid in understanding the balancing factors to leverage 
the translational potential of an animal model for cartilage repair, and employed the information 
to outline repair strategies and to further refine control groups and outcome measures. 
Outcome assessments of typical small animal models (e.g., rodent, rabbit) are mechanical 
testing, histology, immunohistochemistry, imaging, and gross morphological scoring. Outcome 
measures in induced defect live-animal models such as sheep, dogs, and horses include 
arthroscopic scoring, computed tomography (CT), radiograph, visual analog scale (VAS) for 
pain assessment, range of motion, muscle mass around the defect area, kinematics, and India ink 
staining for select biopsied tissue in addition to the ones described above.
35, 111
 
Immunohistochemistry is specifically relevant for large animal studies for elucidation of 
collagen II and aggrecan content and distribution.
111, 161
 Specifically, please refer to Table 2.5 in 
Stannard et al.,
49
 entitled “Comparison of common used animals models for cartilage 
regeneration,” which outlines the benefits and challenges of using different animal models for 
demonstrating cartilage repair. The specific columns entitled “cartilage thickness” and “primary 
use” clearly correlate with each other, and outline the data one can obtain from using a specific 
animal model, thus enabling the investigators to have an informed decision and understand the 
capability of the outcome measures. Additionally, the testing paradigms and measurement 
criteria are similar in both induced defect and animals with natural ailments. The FDA Guidance 
to Industry
115
 indicates that they consider goats, sheep, and horses as acceptable pre-clinical 
models. The articular cartilage thickness in the horse is closest to that in humans. However, goats 
and sheep are recommended given that horses have much larger joints and forces, and are not 
necessarily a relevant model for the veterinary market as patients, nor are they an ethically 






models, establishment of an appropriate control comparator group is required, preferably 
microfracture. Additionally, while employing pluripotent stem cells, issues such as ethical 
concerns, long-term stability, tumorigenesis and mutagenesis must also be considered.   
However, the challenge with microfracture in sheep and goats is mimicking the continuous 
passive motion (CPM) and restricted weight bearing rehabilitation protocol used with human 
patients, which lasts several weeks. Although no model will be perfect for mimicking the 
restricted weight bearing period, investigators may consider limited activity, for example, being 
kept in smaller pens for a period of several weeks before returning to normal activity. Two 
important documents for preclinical cartilage repair studies are the Standard Guide for in vivo 
Assessment of Implantable Devices Intended to Repair or Regenerate Articular Cartilage
35
, by 
the American Society for Testing and Materials (ASTM), and the FDA Guidance for Industry.
115
 
These documents convey the requirements for the approval of drugs, biologics, devices, or 
combination products intended to repair or replace cartilage in the knee, and serve as a 
“roadmap” for gaining clinical approval. It is beyond the scope of the current review to delve 
into FDA and ASTM guidelines, but several reviews and letters have covered the topic Two 
important documents for preclinical cartilage repair studies are the Standard Guide for in vivo 
Assessment of Implantable Devices Intended to Repair or Regenerate Articular Cartilage
35
, by 
the American Society for Testing and Materials (ASTM), and the FDA Guidance for Industry.
115
 
These documents convey the requirements for the approval of drugs, biologics, devices, or 
combination products intended to repair or replace cartilage in the knee, and serve as a 
“roadmap” for gaining clinical approval. It is beyond the scope of the current review to delve 





extensively, which the reader is encouraged to read.
177, 195, 215
 Based on the requirements of a 
typical clinical study, it can be said that a team of a biostatistician, an FDA regulatory consultant, 
a veterinarian, a biomedical engineer, an experienced orthopedic surgeon, and experts in 
biomechanical testing, musculoskeletal histology, and diagnostic imaging is necessary to 
overcome the challenges associated with clinical trials. 
 
Preclinical and simultaneous veterinary market approach 
Figure 2.1, adapted from Lee et al.,
144
 shows a logical progression from lab-based research to 
clinical trials, where stage 2 of research and development branches out to two animal-based 
applications: preclinical data and veterinary medicine. The numerous approaches to cartilage 
therapy have increased the veterinary market population. Pre-clinical studies conducted in 
domestic animals such as dogs have facilitated rapid translation into veterinary medicine,
49
 
closing a gap between the human and veterinary markets. Transparent publication of methods 
and results by the scientists who conduct large animal studies will help to establish a unified 
protocol, useful for future investigators. The existing use of cartilage therapy in veterinary 
medicine creates an exciting opportunity for collaboration between veterinarians and physicians 
to advance the treatment of injury and disease in both human and animal patients. 
 
FEDERAL REGULATIONS AND CLINICAL STUDY CONSIDERATIONS 
The only cell-based FDA-approved product in the Unites States is Genzyme’s Carticel®, a 





DeNovo® ET by Zimmer.
273
 The FDA in the USA has issued specific IND/IDE guidelines on 
cartilage therapy, and, depending upon the nature of the product, they are classified into different 
categories and accordingly handled by the designated control centers.
166
  
Overall, careful design of the clinical study, selection of intervention and comparator group, 
patient population, factors affecting enrollment and clinical endpoints, choosing appropriate 
investigators and medical clinic(s), and allocation of proper funds is crucial for the success of 
any clinical trial. Special emphasis is laid on choosing the appropriate patient population that 
targets the appropriate indication, as it is crucial to demonstrate efficacy of the drug/product in 
disease treatment. In addition to careful selection, clinical endpoint determination must be 
formulated in reference to previous successful and unsuccessful clinical trials, collaboration with 
research scientists, orthopedic surgeons, regulatory personnel, and technicians to ensure 
standardization of testing procedures in the event of a multi-center study. Additionally, the FDA 
considers post-surgery follow-up a significant concern; obtaining more than 85% short and long-






Cartilage repair therapies include primary and secondary outcome measures, which measure pain 
and/or function using well-defined scales
177
 determined by the FDA. Apart from including robust 
primary and secondary outcome measures, including too many individual measurements in a 
primary endpoint can be limiting financially and prove detrimental to the overall success of both 
the treatment and control groups. Primary evaluation endpoints are based on pain and function 







 and enrollment numbers for statistical considerations. The endpoints 
for the purpose of clarity are divided into pain scoring and function scoring, and are typically 
comprised of: 
Pain-based: 
I. Knee Injury and Osteoarthritis Outcome Score (KOOS) 
II. International Knee Documentation Committee (IKDC) Subjective Knee Evaluation 
Form 
III. Symptom Rating Form 
IV. Western Ontario and McMaster University Osteoarthritis Index (WOMAC) 
V. Knee Society Score (KSS) 
Function-based: 
I. Cincinnati Knee Rating System 
II. Structural changes (MRI & MOCART) 
The recommended primary and secondary tests included criteria for advanced stage arthritis and 
for sports-related injuries
213
 with recommendations from the International Cartilage Repair 
Society (ICRS). Pain is an important measurement, crucial to the success of the product, and is 
usually examined as an addition to the primary endpoints (WOMAC/KOOS pain analysis) or as 




For most devices, tissue remodeling of the cartilage repair are typically measured non-invasively 
using magnetic resonance imaging (MRI) and magnetic resonance observation of cartilage repair 





volume loss, and repair tissue characteristics are all considered as crucial secondary endpoints 
that demonstrate product efficacy, which further require standardization and validation across 
several instruments.
24, 93
 However, for specific drugs that delay the onset of cartilage 




Once again, the emphasis lies on selecting important primary and secondary endpoints and 
ensuring the elimination of redundant data sets. Maintaining uniform measurements throughout 
the study and throughout all of the campuses in cases of multi-center trials is of paramount 
importance, as this uniformity affects the overall quality of the data. Standard protocols, uniform 
time points, and diligent reporting of any aberrant information ensure hassle-free and expedited 
review of the data. In addition, clinical measurements including general health data, 
reimbursement outcomes, and overall quality of life can be collected and positively used to 
obtain for the product in the market. 
 
The primary outcome measures in clinical studies, namely pain and function, are different from 
preclinical studies, where the emphasis is on an objective analysis of cartilage 
morphology/structure. This difference can pose challenges in designing the clinical study and 
selecting outcome measures that will demonstrate the advantages of the therapy in a 
practical/feasible manner for clinical investigators and patients. Clinical studies of ACI vs. 
microfracture, in which repair tissue was biopsied and evaluated histologically, did not find an 
association between better structural repair and improved clinical outcomes (pain and function) 
at 1-2 years follow up.
130
 Studies of ACI using a characterized cell therapy (termed 





demonstrate superior clinical outcomes over microfracture until 3 years post-surgery;
216
 the 
clinical outcomes were again comparable between the two groups at 5 years, except for a cohort 
of patients that were treated early (<3 years from onset of symptoms) who did experience clinical 
benefits with CCI.
251
 This finding suggests that the clinical benefits of producing more hyaline-
like repair tissue may take many years to translate into improved clinical outcomes, and may be 
restricted to certain patients/injuries. Consequently, clinical trials for cartilage repair 
technologies may require long-term follow up and careful enrollment to reach endpoints, thereby 
increasing the financial burden of product development. Ongoing work in the development and 
validation of new biomarkers for cartilage repair and joint preservation will be valuable for the 
translation of cartilage repair technologies, especially if biomarker(s) can be used at early time 
points to predict long term outcomes.  
 
OTHER COMMERCIALIZATION CONSIDERATIONS 
It is important to note that FDA approval of a cartilage repair therapeutic, regardless of the 
specific regulatory pathway, depends not only on completion of a successful clinical trial, but 
also on establishment of design control, GMP manufacturing processes, and quality control 
systems to ensure safety and efficacy of drug/device products.  FDA clearance of a device/drug 
and medical need do not guarantee coverage by insurance companies. Therefore, a 
reimbursement strategy is often critical to the commercial viability of a cartilage repair product. 
While the FDA focuses on safety and efficacy, insurance companies focus on superiority of the 
product relative to the gold standard, and economic evaluation (eg. cost per quality adjusted life 
year).
175
 To determine coverage, it is possible that insurance companies may require data beyond 





care, depending on if/how the clinical study was conducted. It may be advantageous to consider 
the requirements for FDA approval and reimbursement simultaneously in designing the clinical 
efficacy study.  
 
CONCLUSIONS 
Although there are several surgical and tissue engineering-based treatments that treat 
osteoarthritis and other cartilage disorders of the knee that have achieved differential success 
rates for both short and long terms, a successful product line recommended uniformly across all 
healthcare facilities does not exist. While many upcoming products are at different stages in their 
FDA trials, there is still an unmet need for a translational technology for cartilage tissue 
engineering.  
 
Common tissue engineering approaches for cartilage regeneration can be broadly divided into 
cell-based and material-based strategies. Cell-based strategies include autologous or allogeneic 
chondrocytes, bone-marrow mesenchymal stem cells, and adipose-derived stem cells. Currently, 
under the FDA, the only cell-based therapy is Carticel from Genzyme. While cell-based 
therapies offer great potential for regeneration, they require two surgeries (if autologous) and can 
be costly. Allogeneic treatments offer greater convenience, but carry additional risks of infection, 
immune rejection or graft-versus-host-disease, which makes the cell-based therapy system 
financially demanding, and a long path to FDA approval.   
 
Material-based strategies such as osteochondral plugs and injectable paste-like materials offer a 
one-step solution, which is financially appealing, and may ensure uniform treatment across 





long-term efficacy in terms of cartilage repair and functional restoration of a device system has 
not yet been demonstrated. Currently, Zimmer Orthobiologics is in the final stages of obtaining 
FDA clearance and around five other products from different companies based in other countries 
are in phase 3 or 4 clinical trials in the brink of securing approval to use in respective countries. 
 
Drugs, on the other hand, consist of predominantly intra-articular injection or oral capsules taken 
by the patient at regular time intervals, although demonstrating efficacy with these approaches 
for treating large defects or advanced stage osteoarthritis has proven to be difficult. Such 
injections are expensive and are mostly focused on relieving pain. While such approaches may in 
general not be considered regenerative medicine strategies, they reduce pain and restore daily 
function for a finite period of time. 
 
The time period from commencing feasibility (i.e., phase 0) clinical trials to actual product sales 
in the market is dependent on several factors, such as success of the clinical trials, selection of 
primary and secondary endpoints for the clinical study, establishment of approved protocols, 
creation of a manufacturing process to meet GMP standards, and working with a fine team to 
address concerns. One important factor to consider is the selection of a proper comparator group 
(i.e., control, standard of care). The information from clinicaltrials.gov suggests that ACI, OATS, 
and microfracture are commonly used as comparators for most devices and biologics, with a 
trend toward using microfracture for late phase clinical trials. Owing to being the most common 
surgical treatment for cartilage injury, and having zero product cost, microfracture is the gold 
standard of comparison that orthopedic surgeons will need to see a product surpass if a company 





preferred control group for clinical trials, and we recommended it as the comparator for pre-
clinical and even small animal cartilage repair studies as well.  
 
It is worth emphasizing that microfracture may also be a desirable first step for certain cartilage 
repair devices. For example, a porous chondral-only (as opposed to osteochondral) device 
approach could leverage the infiltrating cells from the marrow for cartilage regeneration as 
opposed to requiring exogenously seeded cells prior to the surgery. 
 
In addition to selecting an appropriate comparator, other important factors that need to be 
emphasized for running successful clinical trials include knowledge of common inclusion and 
exclusion criteria, strategies to improve the power of the clinical trial, ensuring successful 
enrollment, choosing the right geographic location, and establishing uniform data collection in 
the case of multicenter trials. As already mentioned, adequate care must be taken to include pain 
measurement and important primary and secondary endpoints that can also be used for future 
funding agencies. 
 
In general, the route taken to achieve federal regulatory approval may seem daunting, but with 
multi-disciplinary expertise, an understanding of the dynamic regulations, and lessons learned 














“Raw materials,” or materials capable of serving both as building blocks and as signals, which 
are often but not always natural materials, are taking center stage in biomaterials for 
contemporary regenerative medicine. In osteochondral tissue engineering, a field leveraging the 
underlying bone to facilitate cartilage regeneration, common raw materials include chondroitin 
sulfate (CS) for cartilage and β-tricalcium phosphate (TCP) for bone. Building on our previous 
work with gradient scaffolds based on microspheres, here we delved deeper into the 
characterization of individual components. In the current study, the release of CS and TCP from 
poly(D,L-lactic-co-glycolic acid) (PLGA) microsphere-based scaffolds was evaluated over a 
time period of 4 weeks. Raw material encapsulated groups were compared to ‘blank’ groups and 
evaluated for surface topology, molecular weight, and mechanical performance as a function of 
time. The CS group may have led to increased surface porosity, and the addition of CS improved 
the mechanical performance of the scaffold. The finding that CS was completely released into 
the surrounding media by 4 weeks has a significant impact on future in vivo studies, given rapid 
bioavailability. The addition of TCP seemed to contribute to the rough external appearance of the 
scaffold. The current study provides an introduction to degradation patterns of homogenous raw 
material encapsulated scaffolds, providing crucial characterization data to advance the field of 
microsphere-based scaffolds in tissue engineering. 
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Biphasic and gradient scaffold fabrication are attractive approaches for interface tissue 
engineering applications,
69
 demonstrating that microspheres can offer spatial patterning with 
different microsphere layers possessing different degradation kinetics. New methods to 
incorporate raw materials in biodegradable scaffolds are constantly being explored as they 
enhance regeneration.
43, 147, 182
 Raw material encapsulation in turn alters degradation rate and the 
associated polymer composition that eventually leads to a potential to fabricate desirable 
degradation rate for improved regeneration. Polymer selection, encapsulation of bioactive 
factors, and alterations in porosity are some of the key techniques employed to tune the 
degradation rate of biodegradable scaffolds to best coincide with the rate of tissue regeneration.  
 
 With respect to in vivo osteochondral applications, it would be highly desirable to have a 
gradient pattern, where for example the cartilage section of the scaffolds have a faster 
degradation rate to allow faster access for released chondroinductive signals, and 
correspondingly a slightly slower degrading section for the bone region to provide better 
mechanical support. Particularly, the changes in the degradation rate in the first month impacts 
the initial cellular differentiation and sets the stage for downstream regeneration processes. In 
view of the imminent translational applications, we chose the polymer formulation that was 
employed in a Coulter Foundation-funded sheep study 
181
 and input from regulatory consultants.  
 
The goal of the current study was to fabricate microsphere-based scaffolds with different raw 
materials, and to observe the material properties over time using scanning electron microscopy 







 Polymeric scaffolds were fabricated using biodegradable PLGA 
microspheres that encapsulated TCP or CS as the raw materials.
182
 These unique microspheres 
were fabricated and characterized for degradation in an acellular environment over a period of 4 
weeks. Throughout the study, the raw material encapsulated groups were compared to their 
respective control groups, which were composed solely of the polymer. 
  
 
MATERIALS AND METHODS 
 
Materials 
Faster degrading poly(D,L-lactic-co-glycolic-acid) (PLGA) (50:50 lactic acid:glycolic acid, ester 
end group, Mw = 106 kDa) of intrinsic viscosity 0.6-0.8 dL/g, and slower degrading PLGA 
(75:25 lactic acid:glycolic acid, ester end group, Mw = 112 kDa) of intrinsic viscosity 0.6-0.8 
dL/g were purchased from Evonik Industries
 
(Birmingham, AL). The raw materials were 
chondroitin sulfate A sodium salt (CS) and β-tricalcium phosphate (TCP), which were obtained 
from Sigma (St. Louis, MO). All reagents and organic solvents utilized were of cell culture or 
ACS grade. 
 
Microsphere fabrication  
Four different types of microspheres were fabricated. The microspheres for the study groups 
were CS microspheres (50:50 PLGA+CS+NaHCO3, 77.5:20:2.5 by weight) and TCP 
microspheres (75:25 PLGA+TCP, 90:10 by weight). The microspheres for the control groups 
were “CS control” (50:50 PLGA+NaHCO3, 97.5:2.5 by weight) and a “TCP control” (75:25 





w/v NaHCO3 to 77.5% w/v PLGA (50:50 lactic acid:glycolic acid, ester end group) with intrinsic 
viscosity 0.6-0.8 dL/g dissolved in dichloromethane (DCM) (20% w/v) (Sigma-Aldrich). 
NaHCO3 was dissolved in 0.5 mL deionized water (DI), to which CS powder was added; it was 
then vortexed for 15 minutes to obtain a uniform viscous solution that was subsequently mixed 
with PLGA, dissolved in DCM (20% w/v), and sonicated for 2 minutes. TCP group 
microspheres were fabricated by adding TCP (10% w/v) to PLGA (75:25; 90% w/v) in DCM 





 were prepared according to our previously reported technology
71, 
99, 181, 227, 229
. Briefly, the polymer stream was broken into uniform polymer droplets by exposing 
the stream to acoustic excitation. An annular carrier non-solvent stream (0.5%-2% w/v polyvinyl 
alcohol (PVA) in DI) surrounding the droplets was produced using a nozzle coaxial to the 
needle. The polymer/carrier streams flowed into a beaker containing the non-solvent. The 
polymer droplets were stirred via magnetic stir bar and plated for 3-4 h to allow solvent 
evaporation. Afterward, the polymer droplets were filtered and rinsed in DI to remove residual 
PVA, further lyophilized for 48 h, and stored at -20ºC until further use.  
 
Scaffold assembly 
The microspheres were assembled into a mold (3.5 mm in diameter and 4.5 mm in height) and 
fabricated into scaffolds following an hour sintering with an 95% ethanol-5% acetone solvent 
process as previously reported [5]. All scaffolds in this study were 3.5 mm in diameter and 4 mm 






Scanning electron microscopy (SEM) 
At 1, 2, 3, and 4 weeks, the PLGA scaffolds were collected, freeze-dried overnight, sliced into 
small sections, and set up for sputter coating. The sectioned and dried scaffolds were mounted on 
10 mm aluminum SEM stubs (Ted Pella Inc., Redding, CA) and sputter coated with gold at 30 
mA for 46 seconds in a chamber purged with argon gas. After sputter coating, the samples were 
imaged using a LEO 1550 field emission scanning electron microscope under an acceleration of 
5 kV and high vacuum. 
 
Description of experimental groups 
For the entire study, four different groups were investigated: (i) homogenous microsphere 
scaffolds composed of only 50:50 PLGA+NaHCO3 (ester functional group with intrinsic 
viscosity 0.6-0.8 dL/g), acting as "CS control" (ii) “CS group” microsphere scaffolds composed 
of (50:50 PLGA+CS+NaHCO3) (iii) microsphere scaffolds made of 75:25 PLGA, acting as 
"TCP control" and (iv) "TCP group" microsphere scaffolds composed of 75:25 PLGA 
encapsulated with 20% w/v TCP. Please refer to Table 3.1 for the entire list of experimental 
groups and their abbreviations. 
 
Sample collection 
The microsphere-based scaffolds of all the experimental groups were put in 24 well-plates and 
incubated in sterile phosphate buffered saline (PBS) (ThermoFisher) that was stored at 37°C and 
5% CO2 jacket controlled incubator with access to fresh air.  The PBS was changed every other 






Dry weight analyses 
At weeks 0, 1, 2, 3, and 4, the scaffolds and release media were collected and filtered. The 
recovered microspheres were freeze-dried, weighed [dry weight (t)], and stored at 4°C for further 
analysis. 
The relative dry weight of the scaffold at time t was calculated as follows: 
Dry weight(%)(t) =
Dry weight(t)
Dry weight(t = 0)
. 100% 
Where dry weight (t = 0) denotes the initial dry weight of the microsphere scaffolds (before 
exposure to PBS). 
 
Molecular weight determination 
The molecular weight of the polymeric scaffolds (n = 4) at specific time points (weeks 0, 1, 2, 3, 
and 4) was determined using a Shimadzu LC-20AB HPLC pump equipped with a Shimadzu 
RID-10A refractive index detector (Shimadzu Scientific Instruments, Columbia, MD). Briefly, 
lyophilized scaffolds were dissolved in chloroform to form a final concentration of 0.5% 
polymer and passed through a 0.22 μm syringe filter (BD Biosciences, San Jose, CA) to remove 
any insoluble components. After a brief centrifugation at 5,000 rpm for 10 minutes, the 
supernatant was collected for further analysis. Chloroform was used as the mobile phase with a 
flow rate of 1 mL/min and a column temperature of 40 °C. The molecular weight of the polymers 
was determined relative to the molecular weight of the polystyrene standards (Viscotek, 
Malvern, UK), and weight average molecular weight was calculated from the HPLC plots. 
 





As previously reported, the amount of CS retained within the scaffold was measured by 
dissolving the polymeric constructs in 1 mL of DCM. To each polymeric construct, 0.5 mL of DI 
was added to extract the CS into the aqueous phase. The quantity of CS retained in the scaffold 
(n=4) was measured by the Blyscan dimethylmethylene blue (DMMB) assay (Biocolor, 
Newtownabbey, Northern Ireland). 
 
Calcium in TCP group scaffolds 
TCP group scaffolds were dissolved in 1 mL of DCM (dichloromethane) followed by the 
addition of 0.5 mL of DI to precipitate the calcium ions into the aqueous phase. After a brief 
centrifugation at 5,000 rpm for 10 minutes, the calcium content was measured via the 
QuantiChrom
TM
 calcium assay kit (DICA-500; Hayward, CA) according to the manufacturer’s 
instructions. The final values were read using a UV microplate reader (Thermo Electron 
Corporation, Waltham, MA), measured at 620 nm.  
 
Mechanical Testing 
Unconfined compression was performed using a uniaxial testing apparatus (Instron Model 5848, 
Canton, MA, 50 N load cell) according to our previously reported method. Briefly, following a 
tare load (0.05 N), scaffolds were compressed to 15% strain at a rate of 1% per second under 
PBS at 37 ᵒC, similar to our previous testing.
227
 The elastic moduli were obtained from the linear 
regions of the stress–strain curves. Stress was defined as the ratio of the load to the initial cross 
sectional area, and strain was defined as the ratio of the change in the length to the original 
length. Mechanical testing was performed for all of the scaffolds at weeks 0 (i.e., 24 h), 1, 2, 3, 







Statistical analyses were performed using a one-way analysis of variance (ANOVA) with 
Minitab 17.0 software (Minitab Incorporated, State College, PA), in conjunction with a Tukey’s 
post hoc comparison test for repeated measurements. The statistical significance threshold was 





SEM characterization of scaffolds 
The fabricated microspheres were uniform in size and overall were porous in nature (Fig. 3.1). 
The PLGA-only scaffolds exhibited a smooth surface topology; an effect observed due to the 
ethanol acetone sintering,
230
 while the CS group displayed minute pores on the microsphere 
surface. TCP group exhibited rough patches on the surface compared to its control group. Over 
the period of 4 weeks, both the CS group and CS control group displayed macroporous 
degradation, with the CS control group losing complete structural integrity by week 3 and 
becoming paste-like by week 4. The CS group microspheres, on the other hand, retained their 
macroporous shape until week 4. The TCP control microspheres retained their original shape and 
showed little to no degradation, macroscopically, even at week 4. Conversely, the TCP group 
showed increased surface area roughness and did not degrade macroscopically until week 4.  
 
 





Figure 3.2a represents the percentage dry weight of all of the microsphere-based scaffolds over a 
period of 4 weeks. The CS control group did not have any significant change in weight from 
week 0 to week 2, but decreased by 13.4% from week 0 to week 3 (p < 0.05). By week 4, the CS 
control group had a significant 99.6% decrease from week 0 (p < 0.05). The CS group also did 
not show any significant difference in dry weight content from week 0 to week 2, but decreased 
by 52% from week 0 to week 3, and by 97.1% from week 0 to week 4 (p < 0.05). In comparing 
the CS group to its control, at week 3, we observed that the CS control had a 1.9-fold higher dry 
weight than the CS group (p < 0.05). However, there was no statistically significant difference 
between these two groups at other time points. There were no statistically significant changes in 
dry weight over time, or between the groups, for the TCP group and its control.  
Figure 2b represents the weight-average molecular weight (Mw) of all of the microsphere-based 
scaffolds over the period of 4 weeks. The CS control group was measured to have a starting Mw 
of 339  9 kDa and there was no significant change in Mw over the period of 4 weeks. The CS 
group had a starting Mw of 342  11 kDa, and there was a 9.2% decrease in Mw from week 0 to 
week 4 (p < 0.05). The TCP control group did not have any statistically significant change in Mw 
over time, however the TCP group had a 12.3% decrease in Mw from week 0 to week 4 (p < 
0.05). In comparing the CS and TCP group, the CS group had a 10.5% higher Mw than the TCP 
group only at week 4 (p < 0.05). 
 
Retention of chondroitin sulfate in the CS group scaffolds 
 
The total chondroitin sulfate retained by the CS group scaffolds from week 0 (24 hours) to week 
4 is represented in Figure 3.3a. The GAG value measured from the scaffolds represents the CS 
entrapped within the CS group polymer matrix at the different time points. At week 0, the CS 





0.05). There was a further 74.7% and 64.2% decrease from week 1 to week 2 and from week 2 to 
week 3 (p < 0.05), respectively. By week 4, there was no detectable CS retained in any of the 
scaffolds. 
 
Retention of calcium in the TCP group scaffolds 
The total calcium retained by the TCP group scaffolds from week 0 (24 hours) to week 4 is 
represented in Figure 3.3b. At 24 hours, the TCP group had an average calcium content of 432  
18 μg in the scaffolds, which decreased by 31% at week 1 (p < 0.05). The calcium content in the 
scaffolds decreased by 36.3% from week 0 to week 2 and 59.4% from week 0 to week 3 (p < 
0.05). Finally, there was a 77.3% calcium content decrease in the TCP scaffolds from week 0 to 





There was no significant change in the elastic modulus of the CS control group from week 0 to 
week 2.  However, beyond week 2, these samples became too unstable to be loaded into the 
instrument’s sample holder. The CS group on the other hand had a significant 75.1% decrease in 
elastic moduli only from week 0 to week 3 and 77.2% decrease from week 0 to week 4 (p < 
0.05). There was no significant change in moduli from week 0 to week 2. There was no sample 
at week 4 to make any comparisons. There were no significant differences in the moduli between 
CS control and CS group at the time points where the CS control had available data. The TCP 
control group had a statistically significant 73.6% decrease in elastic modulus from week 0 to 
week 3 (p < 0.05) and no significant change from week 0 to week 2, or from week 0 to week 4. 





2 (p < 0.05). With regard to the TCP group, there was a 43.9% increase in the elastic modulus 
from week 0 to week 3 and a 2.8-fold higher modulus at week 4 compared to week 0 (p < 0.05). 
In comparing the TCP control and the TCP group, we observed that there was a 5.3-fold higher 
compressive elastic modulus for the TCP control group compared to the TCP group (p < 0.05) at 
week 0. In addition, there were 3.1-fold and 1.9-fold higher moduli for the TCP control group 
compared to the TCP group at week 2 and week 4, respectively (p < 0.05). 
 
DISCUSSION 
The current study demonstrated, for the first time, the degradation pattern of nanocomposite 
microsphere-based scaffolds. The gradient capability that we have demonstrated with 
microsphere-based scaffolds allows for CS and TCP to be encapsulated in opposing gradients 
within a single biomaterial construct.
99, 181
 For the first time, we have an understanding of the 
mechanics and the raw material retention within these scaffolds over the crucial first month, 
from which we can quantitatively infer gradients not only in initial material composition, but 
also in mechanics and degradation and release rate. 
We are the first group to vigorously investigate the potential of TCP as a viable raw material for 
microsphere-encapsulation for osteochondral applications. Although other groups have used 
hydroxyapatite-sintered microspheres and carbon-nanotube reinforced scaffolds, no studies have 
fully characterized homogenous TCP-encapsulated, microsphere-based scaffold degradation in 
comparison to the polymer alone.
54, 157, 172
 
The SEM images depicted an overall porous nature of the microsphere-based scaffolds with 
interconnected pores and were in agreement with our previous findings with low molecular 
weight PLGA.
230





embedding and subsequent removal during the scaffold fabrication step, which was consistent 
with our previous publications.
100, 183
 Although the current paper did not measure porosity, 
information can be obtained from our previous manuscripts that use similar formulation.
100
 The 
TCP group on the other hand did not possess porous but had a rough external surface instead. 
The surface characteristics of the raw material encapsulated may have great implications for cell 
anchorage, cell migration and nutrient diffusion. 
The dry weight data were in accordance with the SEM analysis. While both the low molecular 
weight PLGA lost its dry weight completely by week 4, the TCP scaffolds did not have any 
significant change in mass even after week 4. Thus, using a higher molecular weight PLGA that 
had a higher percentage of lactic acid not only delayed degradation on the surface, but also 
maintained its overall mass percentage.  
The GAG and calcium release assay that evaluated the raw material content in the scaffolds were 
consistent with the SEM observations. The starting values of GAG and calcium at week 0 do not 
represent their loading value. This may be attributed to loss during the lyophilization and the 
solvent sintering step. About 60% of the CS was released at week 1 into the surrounding media. 
The relatively high bioavailability of CS within the first week and complete release within one 
month may be highly desirable for initiating a bioactive chondrogenic response in vivo during the 
crucial period of regeneration. 
Mechanical testing results demonstrated the compressive moduli of microsphere-based scaffolds 
to be of similar order of magnitude relative to articular cartilage (0.1–0.9 MPa) and within an 
order of magnitude of the moduli for cancellous bone (0.01–2 GPa).
5, 19, 100, 126
 The elastic 
modulus of the TCP group at week 0 was in agreement with the moduli of calcium phosphates as 
observed by Ly et al.
56





Although the starting modulus of the PLGA groups in the current study are comparable to our 
previous studies, over a period of 4 weeks, there was a an order of magnitude increase in 
modulus for the gradient groups, which may be the combined effect of two types of PLGA and 
the stiffness contributed by cellular differentiation.
72, 100
 In another previous study from our team, 
which employed raw material-encapsulated scaffolds compressed at strain rate of 1 mm/min, we 
observed that the elastic moduli was generally lower than the moduli reported in the current 
study.
183
 However, the previous study employed rat bone marrow mesenchymal stem cells 
(rBMSCs) and gradient scaffolds with a low-molecular weight PLGA. In the current study, while 
the moduli of the TCP control scaffolds did not show any significant change over time, the TCP 
group had a 91.5% increase from week 2 to week 4 (p < 0.05) an observation consistent with our 
previous paper.
228
 Both the CS control and CS groups showed a decline in elastic modulus that 
may be explained by the low molecular weight nature and the high glycolic content of the 
polymer.
3
 PLGA microspheres are known to degrade via bulk erosion where the rate-limiting 
step is the diffusion of water molecules into the microsphere core. CS microspheres, because of 
their porous nature and the hydrophilic nature of CS, may have allowed faster diffusion of the 
water molecules into their core, thereby initiating the polymer degradation more quickly than in 
the other three groups, as evidenced by a significantly greater mass loss by 3 weeks. However, 
the structural integrity of the CS constructs was superior to the CS control through the 4 week 
duration. Additionally, swelling caused by penetration of water inside of the microspheres may 
have also played a role in the drop in elastic modulus of CS scaffolds.
183
 Moreover, the polymer 
composition (75:25 PLGA) and microsphere morphology (absence of minute pores on surface) 
may have allowed the TCP scaffolds to further retain their mechanical properties. The imminent 





and independently correlate the effect of cells versus the effect of raw materials and thus results 
from such studies would be valuable in designing scaffolds for future large animal models.  
Findings from the current study necessitate the need to refine the technology by parameters like 
adjusting raw material and polymer concentration that in turn would modify the degradation rate. 
Since the polymer degradation and the raw material released plays a major role for in vivo 
studies, there is a pressing need to reach a suitable selection of polymer and raw material 
concentration for specific applications. The scaffold selected to treat small animals like rats and 
rabbit may not match the need of a large animal model. Moreover other factors like bone 
stiffness, cartilage thickness must also be considered for enhanced scaffold design. The current 
study attempted to characterize homogenous microsphere-based scaffolds to provide a basis for 
analyzing degradation patterns that in turn would enable multilayered and gradient scaffold 
fabrication. In addition to just altering the degradation kinetics, raw materials can also provide 
beneficial signals to the surrounding cells guiding the differentiation and neo-tissue regeneration. 
 
CONCLUSIONS 
The current study evaluated the degradation properties of raw material encapsulated 
microsphere-based scaffolds over a period of 4 weeks. Overall, the results demonstrated that the 
incorporation of CS with 50:50 PLGA may have increased surface porosity and enhanced the 
structural stability over 4 weeks compared to the polymer without CS. More importantly, about 
60% of the CS encapsulated was released at week 1 and 100% of the CS was released by 4 
weeks. The current finding might have significant implications for the design of future in vivo 





favored a better mechanical response over time and retention of an overall rough surface 
topology even at 4 weeks compared to the TCP control group. Such a complementary nature of 
the encapsulated raw material adds value to the polymer selection, thus aiding the fabrication of 
gradient or multilayered scaffolds with informed decision about degradation. Future studies will 
benefit from expanded analyses to further elucidate the effects of the raw materials on the 
degradation and mechanics of the scaffolding materials over time. 
As an example, for in vivo interface tissue engineering applications that need different 
degradation rates to match the properties of the native tissue, the current study provides a means 
to evaluate the individual parameters involved in assessing the degradation pattern under an in 
vitro setting. The degradation pattern according to this platform can be tailored by polymer 
selection, nature of raw materials that are encapsulated and the concentration of both to 
manufacture the final scaffold. Additionally, the current study also employed a set of raw 
materials (CS & TCP) combined with two specific types of PLGA, and emphasized that the raw 
material content, along with the PLGA composition, are important parameters for controlling 














There are a variety of exciting hydrogel technologies being explored for cartilage regenerative 
medicine. Our overall goal is to explore whether using stem cells in an aggregate form may be 
advantageous in these applications. 3D stem cell aggregates hold great promise as they may 
recapitulate the in vivo skeletal tissue condensation, a property that is not typically observed in 
2D culture. We considered two different stem cell sources, human umbilical cord Wharton’s 
jelly cells (hWJCs, currently being used in clinical trials) and rat bone marrow-derived 
mesenchymal stem cells (rBMSCs). The objective of the current study was to compare the 
influence of cell phenotype, aggregate size, and aggregate number on chondrogenic 
differentiation in a generic hydrogel (agarose) platform. Despite being differing cell sources, 
both rBMSC and hWJC aggregates were consistent in outperforming cell suspension control 
groups in biosynthesis and chondrogenesis. Higher cell density impacted biosynthesis favorably, 
and the number of aggregates positively influenced chondrogenesis. Therefore, we recommend 
that investigators employing hydrogels consider using cells in an aggregate form for enhanced 
chondrogenic performance.  
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The Wharton’s jelly of the human umbilical cord is believed to contain mesenchymal progenitor 
cells 
11
. Wharton’s jelly cells (WJCs), when cultured in chondrogenic medium, have been shown 
to produce elevated expression of cartilage specific genes such as SOX9, collagen II, and 
aggrecan 
214
. Human WJCs (hWJCs) were first introduced to the 3D musculoskeletal tissue 
engineering literature in 2007 
9
, and have since emerged as a promising alternate source of cells 
due to desirable properties such as ease of collection, immunocompatibility, superior tropism, 
and differentiation potential 
59, 63, 125, 152, 256, 258, 259
. 
 
When chondrocytes are plated in monolayer culture, after several passages they lose their native 
phenotype and express collagen I, which is absent in articular cartilage 
114
. The standard method 
for culturing cells for chondrogenesis has been pellet culture, in which chondrogenic 
differentiation is facilitated by the direct cell-cell interaction available in the 3D pellet. Our 
global hypothesis is that multiple aggregates of cells will be able to provide the benefit of cell-
cell interaction relative to non-aggregated cells. Others have reported that microencapsulation of 
aggregates in a hydrogel has resulted in improved chondrogenic differentiation 
81, 150
. 3D 
embryonic stem cell (ESC) aggregates have been shown to initiate chondrogenic differentiation 
51
.  Condensation of cells by reduction in intercellular spaces is favorable for chondrogenesis 
208
, 
and inhibition of cell aggregation delays chondrogenic differentiation 
265
.  
Several studies have explored the use of rat and human stem cell aggregates for musculoskeletal 
applications. In particular, Goude et al. 
94
 reported that MSC spheroids composed of 500-1,000 
cells maintained a structure analogous to cartilage condensation, and the effect of chondroitin 





and aggrecan.  Lei et al. 
145
 reported that MSC spheroids had the therapeutic potential to treat 
repaired cartilage tissue. When grown as spheroids and supplemented with TGF-β1-encapsulated 
gelatin microspheres 
57
, human adipose-derived stem cells (hADSC) were shown to differentiate 





To the best of our knowledge, never before have hWJC aggregates been fabricated in a 3D 
platform, much less been explored for cartilage tissue engineering applications. Moreover, no 
other study has compared cell suspension and aggregates side by side with two different cell 
types. Our overall hypothesis for the current study was that the aggregate groups would 
outperform the cell suspension (CS) groups in chondrogenesis. We further hypothesized that the 
effect of the aggregate model on chondrogenesis would be dependent on the number of cells per 
aggregate. 
MATERIALS AND METHODS 
 
Cell culture and expansion 
hWJC were isolated from Wharton's jelly of five human umbilical cords obtained from the 
Lawrence Memorial Hospital with informed consent (Institutional Review Board Lawrence 
Memorial Hospital Protocol# 08-2, University of Kansas Institutional Review Board, Protocol# 
15402), with all births at full term and under normal delivery conditions. Written consent was 
obtained from the patient and the consent method and cord-harvest for approved for this study by 
the IRB committee. The cord collection and cell harvest was approved by the IRB specifically 
for this study. We isolated hWJC according to our previous published protocol 
64, 169





cells were cultured in hWJC media, which was composed of 10% MSC qualified fetal bovine 
serum (FBS) (Invitrogen Life Technologies, Carlsbad, CA) and 1% Penicillin-Streptomycin 
(Invitrogen Life Technologies, Carlsbad, CA) in low glucose DMEM (Life Technologies, Grand 
Island, NY). The medium was changed every other day, and hWJCs were maintained at 37°C 
with 5% CO2 in a cell culture grade incubator. At 80% to 90% confluence, hWJCs were 
trypsinized with 0.05% Trypsin-EDTA (Life Technologies) and expanded in this fashion up to 
passage 4 (P4). Cells at P4 from all five cords were pooled into one tube.  
Rat bone marrow-derived mesenchymal stem cells (rBMSC) were harvested from the femurs of 
seven young male Sprague–Dawley rats (200–250 g, Charles River) following a University of 
Kansas approved IACUC protocol for cellular harvest protocol# 175–08. The femur harvest and 
cell isolation was approved specifically for this study. The cells were isolated according to a 
protocol previously reported by our lab 
9
. Briefly, isolated cells were cultured in rBMSC media 
(αMEM supplemented with 10% MSC qualified FBS (Life Technologies, Grand Island, NY) 1% 
Penicillin-Streptomycin (Invitrogen Life Technologies, Carlsbad, CA) and passaged at 80% 
confluence until P4. All cells from different femurs were pooled together at P4, and used for the 
study. 
The rationale for use of rat BMSCs instead of human BMSCs is for reproducibility, i.e., the 
opportunity to procure rats of the same strain, age and gender, thus removing the inherent 
variability associated with adult human BMSC donors.  With umbilical cords all coming from 
patients of the same age (i.e., birth), this concern of age variation that applies to BMSCs does not 
apply to WJCs. The objective of the study was not to make broad general conclusions about 





different results when different sources of mesenchymal cells are used, including their respective 
different species and culture medium compositions prior to encapsulation in agarose. 
 
Cellular aggregate formation 
Aggregates for the current study were generated by the hanging drop technique.
243
 Cellular 





 cells/mL, in respective media. Droplets of cell suspensions at a controlled volume of 10 
μL that had 10,000 or 20,000 cells, respectively, were pipetted in an array onto the inside surface 
of a petri dish lid using a 10 μL pipette (Eppendorf, Hauppauge, NY), making sure that the 
droplets had a safe distance between each other to prevent collision. The cells were allowed to 
aggregate overnight, aided by gravity when the petri dish was reversed (Fig. 1). The petri dish 
bottom was then filled with PBS to prevent drying of these droplets. After 24 hours, the cell 
aggregates were collected from the dish with a 1 mL pipette and then encapsulated in agarose 
hydrogels as described below.  
 
Encapsulation of cells in agarose hydrogels 
Phosphate-buffered saline and low temperature gelling agarose (Type VII- A#A0701) were 
purchased from Sigma-Aldrich (St. Louis, MO). All other chemical reagents and solvents were 
of analytical reagent grade. Agarose was prepared according to a previously reported protocol 
61
. 
Briefly, 0.3 grams of agarose was added to 10 mL of PBS and autoclaved for 30 minutes to 
create a 3% (w/v) agarose solution. The agarose solution was cooled to 39 C after autoclaving. 
Next, CS or aggregates were pipetted into the agarose solution accordingly. Table 4.1 gives a 





the “low aggregate number” group, one to four aggregates were encapsulated in a single agarose 
hydrogel, and for the “higher aggregate number” group, five to seven aggregates were 
encapsulated in a single agarose gel. The aggregates were pipetted into the agarose solution gels 
very quickly, thus giving only a few seconds of working time and so a few aggregates were 
always lost in the micropipette tip. To account for the loss in pipetting, a range of numbers (1-4): 
LA and (5-7): HA was denoted. Using the same number of cells per hydrogel, corresponding 
controls (cell suspension) were fabricated. For the CS groups, the required amount of cells was 
pipetted into the agarose solution at 37C and pipetted gently up and down, then poured into 
sterile airtight silicone molds (5 mm diameter x 1.9 mm height) and refrigerated at 4C for 3-4 
minutes. The molds were then retrieved, and the constructs were punched out into a 24 well plate 
(Sigma-Aldrich, St. Louis, MO) and incubated with medium composed of high glucose DMEM 
(Invitrogen, Carlsbad, CA) with 4.5 g/L D-glucose supplemented with 10% MSC fetal bovine 
serum (FBS), 1% non-essential amino acids, 1% sodium pyruvate, 50 μg/mL ascorbic acid, 
0.25 mg/mL penicillin-streptomycin-fungicide and 100 ng/mL human transforming growth 
factor (TGF)-3 (PeproTech Inc., Rocky Hill, NJ) at 37C and 5% CO2. All of the aggregate 
groups had corresponding controls except hWJC 20M HA, which did not have 20M HA CS, as 
there were not enough cells to make the control groups. Medium was made fresh every other day 
to avoid freeze-thaw cycles and thus to preserve the bioactivity of TGF-3, and changed every 
other day. 
 
Cell viability assay 
To check the viability of the encapsulated cells and aggregates on agarose scaffolds, a 





The samples were washed once with PBS and incubated in live/dead staining solution (0.5 µL 
calcein and 2.0 µL ethidium homodimer-1 (ETH) diluted in 1 mL DPBS) for 10 min (37C, 5% 
CO2). The samples were once again washed with PBS prior to imaging using an inverted 
epifluorescent microscope (Zeiss-LSM 710, Thornwood, NY). Live and dead cells were 
respectively stained green and red, and the process was repeated on the study groups 
(aggregates) and the control groups (cell suspensions). 
 
Biochemical analysis 
DNA analysis:  
Constructs were removed from culture in a sterile manner, crushed manually using pipette tips, 
and incubated in a papain digestion solution consisting of 125 mg/mL papain, 5 mL N-acetyl 
cysteine, 5 mL ethylenediaminetetraacetic acid, and 100 mL PBS (all reagents from Sigma-
Aldrich, St Louis, MO) in distilled water overnight in a 60C water bath. The next day, sample 
digests were centrifuged for 5 minutes and stored at -20 C until further use. DNA content was 
quantified for all samples utilizing a PicoGreen kit (Molecular Probes, Eugene, OR) according to 
the manufacturer’s instructions. Previous studies
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 from our lab established a conversion factor 
of 8.5 pg/cell that may be used to convert DNA content to cell number for human cells. For the 






For quantifying collagen production, a Sircol soluble collagen assay kit and manufacturer’s 





water) were incubated in pepsin solution (Sigma-Aldrich) and stored overnight at -4C. The kit 
provided standards, and distilled water was used as the blank. 1.0 mL of Sircol dye reagent and 
100 µL of each sample were mixed slowly for 30 minutes. Solutions were centrifuged at 12,000 
rpm for 10 minutes, and the resulting supernatant was discarded, keeping the pellet intact. The 
previous step was repeated after the addition of 750 µL of ice-cold acid salt wash. The pellet was 
resuspended, and 250 µL of alkali reagent was added. Solutions were then vortexed thoroughly 
and 200 µL of the solution was transferred to a 96-well plate and read at 555 nm in a Multiscan 
Ascent microplate reader (Thermoelectron Corporation, Waltham, MA). The exact same 




GAG content was measured with the Sircol DMMB assay kit and manufacturer’s protocol 
(Biocolor B1000 Belfast, U.K.) was followed. Constructs were homogenized with the 
aforementioned papain digesting solution and left in a 60C water bath overnight prior to 
measuring increase in glycosaminoglycan (GAG) content. A chondroitin sulfate standard was 
provided with the kit, and distilled water was again used as the blank. 1.0 mL of 
dimethylmethylene blue dye solution was added to 100 µL of sample, standard, and blank. 
Solutions were mixed slowly for 30 minutes and centrifuged for 10 minutes. The supernatant 
was discarded, the pellet was resuspended, and 1.0 mL of dissociation solution was added. The 







Gene expression analysis 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was used to assess gene 
expression levels for collagen types I, X; aggrecan; SOX9; GADPH; and Runx2. Collagen II 
primer was not considered due to high variability in results even after multiple trials. To each 
sample, 1.0 mL of lysis buffer (Qiagen, Germantown, MD) was added, and after 1 hour, the 
solutions were homogenized with a QIAshredder column (Qiagen 79656, Germantown, MD) to 
extract messenger RNA (mRNA) in accordance with the RNEasy Plus Mini Handbook. A high 
capacity cDNA reverse transcription kit (Applied Biosystems 4368814, Foster City, CA) allowed 
reverse transcription of mRNA to complementary DNA (cDNA). 10 µL of the master mix and 
RNA samples were combined in a 96-well plate, which was then loaded into an Eppendorf 
Realplex Mastercycler (Eppendorf, Hamburg, Germany). cDNA concentrations were normalized 
with DNASE-free water, and a Taqman gene expression assay kit (Applied Biosystems) 
provided the seven primers for the above-mentioned genes (Table 4.2). 1 µL of cDNA from each 
sample, 10 µL of universal fast master mix (2x), and 1 µL of a specific primer were mixed in a 
96-well plate. RT-PCR reactions were then run in an Eppendorf Realplex Mastercycler. 
 
Immunohistochemistry 
Frozen hWJC and rBMSC scaffolds were embedded in Optimal Temperature Cutting (OCT) 
medium (TedPella Inc, Redding, CA) overnight at 37C and frozen at -20C until further use. 10 
µm sections were generated using a cryostat (MICROM HM 550, Thermo-Fisher, Carlsbad, 
CA). The sectioned aggregates taken at week 0, week 2, and week 3 time points for both 10M 
and 20M samples were kept frozen at -20C prior to staining. Thawed samples were fixed with 





in 0.1% triton X for 5 minutes (all reagents from Sigma-Aldrich, St. Louis, MO). The sections 
were exposed to 3% hydrogen peroxide in methanol for 10 minutes to suppress endogenous 
peroxidase activity, and the slides were immediately incubated in proteinase K (IHCWORLD 
IW-1101, Woodstock, MD) at 37C for 10 minutes. Sections were blocked with 3% blocking 
serum (Vector Laboratories S-2012, Burlingame, CA) for 30 minutes preceding primary 
antibody incubation for collagen I, collagen II, and aggrecan for 30 minutes (Table 4.1). 
Following primary antibody (Lifetechnologies, Carlsbad, CA) incubation where all of the 
primary antibodies were rabbit IgG, slides were exposed to biotinylated secondary antibody 
(horse anti-rabbit IgG) and ABC reagent (Vectastain ABC kit PK-6200, Burlingame, CA) for 30 
minutes each. Lastly, the ABC reagent was added to the sections after washing with PBS and 
incubated for 30 minutes and then washed again. Visualization was accomplished with ImmPact 
DAB peroxidase substrate (Vector laboratories SK-4105, Burlingame, CA) before rinsing with 
distilled water and counter stained with VECTOR hematoxylin QS stain. Following staining, 
slides were rinsed in tap water; dehydrated in ethanol, cleared in xylene for mounting (Permount 
SP15-500 Fair Lawn, NJ), and viewed under an upright microscope (Zeiss, Axiomanager 2.0, 
Thornswood, NY). Negative controls for IHC consisted of isotype IgG controls (Life 
Technologies) being added instead of the primary antibody. 
 
Statistical analyses 
All data are expressed as average ± standard deviation. Statistical analyses were performed using 
one-way ANOVA (Minitab 15, Minitab Incorporated, State College, PA), followed by a Tukey’s 
post hoc comparison test for repeated measurements. The statistical significance threshold was 








Cell viability overall was quite high. Compared to the 20M aggregate groups, the 10M LA and 
10M HA grouops had relatively higher densities of live cells at week 3 than at week 0 (Fig. 2). 
20M aggregates exhibited some cell death right from week 0, and all of the HA groups had more 
visible dead cells than the LA groups for both 10M and 20M at week 3 compared to week 0. 
Among the aggregate groups, 20M HA, 10M HA, and 20M LA had condensed regions of cell 
death at the aggregate periphery at week 0, whereas cell death was distributed throughout the 
aggregate at week 3. There was no noticeable increase in aggregate diameter over the 3 weeks 
for any of the groups. There was increased cell death in week 3 in 20M HA CS compared to 
week 0, but lesser cell death compared to aggregates.  
 
3.1.2 hWJC 
The 10M LA CS group showed higher cell viability at week 3 compared to week 0; and 10M HA 
CS exhibited its highest cell death rate at week 3 (Fig. 3). 10M LA and HA maintained 
consistent cell viability; however, similar to the rBMSC group, the 20M groups experienced 
relatively more cell death than 10M groups at the week 3 time point. It is also important to note 
that the 10M HA aggregates displayed a tightly condensed aggregate compared to the LA 
aggregates. Week 3 images visibly demonstrated an apparent decrease in aggregate diameter and 
an increase in cell death for 20M LA aggregates. Among the CS groups, the 20M HA and CS 
groups experienced significant cell death at both week 0 and week 3 compared to the LA CS 










The 10M LA CS and 10M HA CS groups increased in DNA content by 2.6% and 2.3%, 
respectively, from week 0 to week 3 (p < 0.05). All other CS groups did not display any 
statistically significant difference in DNA content with respect to time (Figure 4.4 A&B). 
Among the aggregate groups, the DNA content of the 10M LA group decreased by 1.9% from 
week 0 to week 2 with no significant difference at week 3, and the 20M HA group displayed a 
2.5% decrease from week 2 to week 3 (p < 0.05). There were no other significant changes in 
DNA content over time for the other aggregate groups. In comparing the aggregate and 
corresponding CS groups, we saw that at week 0, the DNA content of 10M LA aggregates was 
2.7-fold greater than the 10M LA CS (p < 0.05), but differences were not significant at other 
time points.  
The differences in DNA contents between the 20M LA and 20M LA CS groups were not 
statistically significant at any time point.  
Among the LA groups, the 10M LA and 20M LA groups did not exhibit any statistically 
significant differences in DNA content from each other at any time point. On the other hand, the 
20M HA group at week 2 had the highest DNA content (18.1 μg) among all of the sample groups 
(p < 0.05). At week 0, the 20M LA CS group had 1.7% more DNA content than the 10M LA CS 







Among the CS groups (Figure 4.4 C&D), the 10M LA CS, 10M HA CS, 20M LA CS and 20M 
HA CS groups did not display any significant changes in DNA content over the 3 week period. 
However among the aggregate groups, only the 10M LA group (Figure 4.4C) exhibited a 
statistically significant change over time, with a 1.4% increase in DNA content from week 0 to 
week 2 (p < 0.05). In comparing the aggregate and corresponding CS groups, the 10M LA group 
DNA content was 1.6-fold higher at week 2 compared to its 10M LA CS control group, and at 
week 3 the DNA content of the 10M HA group was 2.6 times higher than that of its 10M HA CS 
control group (p < 0.05). A comparison between the 10M and 20M groups did not show any 





All values are reported on a normalized (to DNA) basis. Among the CS groups, the 10M LA CS 
group (Figure 4.5A) had a 23% increase in GAG/DNA from week 0 to week 2 (p < 0.05) and no 
significant increase from week 2 to week 3. The 20M LA CS group experienced a 21% increase 
in DNA content from week 0 to week 2 (p < 0.05), and no other significant differences from 
week 2 to week 3. The 10M HA CS group had a 43% increase in GAG/DNA content from week 
0 to week 2, and similarly the 20M HA CS group had a 60% increase in GAG/DNA content 
from week 0 to week 2 and no statistically significant increase at week 3 (p < 0.05). Among the 
aggregate groups, the 10M LA group had a 26% increase in GAG/DNA content from week 0 to 
week 2 (p < 0.05), but no significant increase from week 2 to week 3. The 20M LA group had a 





0 (p < 0.05). The 10M HA group (Figure 4.5B) had a 43% increase in GAG/DNA content from 
week 0 to week 2, and the 20M HA group had an 85% increase in GAG/DNA at week 3 
compared to week 0 (p < 0.05), although other differences over time for the HA groups were not 
significant. Comparing the aggregate and corresponding CS control groups, the 20M LA group 
had a 4.2-fold higher GAG/DNA content compared to its 20M LA CS control group at week 3, 
and the DNA/GAG content for the 20M HA group was 2.5-fold higher than its 20M HA CS 
control group at week 3 (p < 0.05). In comparing the 10M vs. 20M groups, 10M HA had 2.7-fold 
higher GAG/DNA content than 20M HA at week 3 (p < 0.05). Similarly, in comparing the LA 
vs. corresponding HA groups, the 20M HA group had a 2.3-fold higher GAG/DNA content than 
the 20M LA group at week 3 (p < 0.05). The 10M LA vs. 10M HA did not display significant 
differences at any of the time points. 
hWJC 
None of the CS groups (Figure 4.5 C&D) showed a statistically significant difference in the 
GAG/DNA content. Except for the 10M HA group, which had a 21% increase in GAG/DNA at 
week 2 compared to week 0, no other aggregate group experienced any significant changes over 
time (p < 0.05). In comparing the control and aggregate groups, only the 10M HA group had a 
2.3-fold higher GAG/DNA compared to the control 10M HA CS at week 2 (p < 0.01). All other 




All of the reported values represent collagen content that is normalized to DNA. Among the 





collagen content over time, with a 75% decrease in collagen/DNA from week 0 to week 2 (p < 
0.05). Among the aggregate groups, there were two statistically significant changes over time. 
First, at week 3, the 20M LA group had a 3.8-fold higher collagen/DNA than at week 0, and the 
20M HA group had an 8.5-fold higher collagen/DNA content at week 3 than at week 0 (p < 
0.05).  In comparing the aggregate and corresponding CS control groups, at week 3 only the 20M 
LA and 20M HA were significantly higher, with 2-fold and 4.6-fold higher collagen/DNA 
contents relative to their respective CS controls (p < 0.05). In comparing the LA vs. HA groups, 
the 10M HA group exhibited an 8.7-fold higher and 72% higher collagen/DNA content than the 
10M LA group, at weeks 0 and 3, respectively (p < 0.05). Similarly, at week 3, the 20M HA 
group had a 4.8-fold higher collagen/DNA content compared to the 20M LA group (p < 0.05). 
Lastly, comparing the 10M vs. 20M groups, we observed that the 20M LA group had a 2.8-fold 
and 2.3-fold higher collagen/DNA content compared to 10M LA group at weeks 2 and 3, 
respectively (p < 0.05). At week 3 alone, the 20M HA group had 5.6-fold higher collagen/DNA 
than the 10M HA (p < 0.05).  
 
hWJC 
Among the hWJC CS groups (Figure 4.6 C&D), only the 10M HA CS group experienced a 
significant change over time, with a 2.3-fold increase in collagen/DNA content from week 0 to 
week 2 (p < 0.05). Among the aggregate groups, there were two statistically significant changes 
over time. First, the 10M LA group at week 3 had a 37% increase in collagen/DNA from week 0 
to week 3, and the 10M HA group had a 4.9-fold increase in collagen/DNA content from week 0 
to week 3 (p < 0.05). No other groups had a significant increase over time. In comparing the 





differences over the period of 3 weeks. First, the 10M LA group at week 3 alone had a 2.7-fold 
higher collagen/DNA content than its 10M LA CS group (p < 0.05). Secondly, the 20M LA 
group at week 3 alone had a 3.1-fold higher collagen/DNA content than its 20M LA CS control 
group (p < 0.05). In addition, the 10M HA group at week 3 alone had a 2.3-fold higher 
collagen/DNA content than its 10M HA CS control group (p < 0.05). Finally, the 20M HA group 
at week 0 had a 63% higher collagen/DNA content compared to its 10M HA CS control group (p 
< 0.05). 
In comparing LA vs. HA, we observed that only at week 3 the 10M HA group had a 2.7-fold 
higher collagen/DNA content compared to the 10M LA group (p < 0.05). There were no other 
statistically significant changes over time for any other group. In comparing the 10M vs. 20M 
groups, there was only one significant difference. At week 0, the 20M HA group had a 7.5-fold 
higher collagen/DNA content than the 10M HA group, but, at week 3, the 20M HA had a 74% 





The 10M LA CS group (Figure 4.7 A&B) had a 3.5-fold increase in expression in collagen I 
gene expression from week 0 to week 2, and the 20M LA CS group had a 10.2-fold increase in 
collagen I expression from week 0 to week 3 (p < 0.05). The 10M HA CS group did not show 
any significant increase in gene expression over time, but the 20M HA CS group had a 97.5% 
increase in gene expression from week 0 to week 2 (p < 0.05). Among the aggregate groups, 





5.6-fold increase at week 2 compared to week 0 and no significant increase at week 3 (p < 0.05). 
Second, the 10M HA group had a 3.6-fold increase in gene expression at week 2 compared to 
week 0 and no significant increase at week 3 (p < 0.05). The other aggregate groups (10M LA 
and 20M HA) did not show statistically significant changes over time. In comparing the 
aggregate and corresponding CS control groups, at week 3, the 10M HA group had a 1.7-fold 
higher collagen I expression compared to its respective CS control group (p < 0.05).  
In comparing the 10M vs. 20M groups, we observed that only at week 0, the 20M LA group had 
83% lesser collagen I gene expression than the 10M LA group (p < 0.05). In comparing the LA 
vs. HA groups, we observed only one significant difference. At week 3, the 10M HA group had a 
2.2-fold higher collagen I gene expression than the 10M LA group (p < 0.05). No other 
differences were significant.  
 
SOX9: 
The 10M HA CS group (Figure 4.7 C&D) had a 3.1-fold increase in SOX9 expression from 
week 0 to week 2, and the 20M HA CS group had a 57% decrease in expression from week 0 to 
week 2 (p < 0.05). Among the aggregate groups, the 10M LA group had a 4.5-fold increase in 
SOX9 gene expression from week 2 to week 3, and the 20M LA group at week 2 had a 34% 
increase in SOX9 expression compared to week 0 (p < 0.05). Additionally, the 10 HA group also 
had a 27% increase in SOX9 gene expression from week 2 to week 3 (p < 0.05). In comparing 
aggregate and control groups, we observed that at week 2, the 10M LA group had a 2.8-fold 
higher SOX9 expression compared to its CS control group (p < 0.05). At week 2 and week 3, the 





(p < 0.05), and the 10M HA group had a 1.4-fold higher SOX9 gene expression compared to its 
CS control group (p < 0.05).  
In comparing the 10M vs. 20M groups, we observed only one statistically significant difference. 
At week 3, the 20M HA group had a 2.6-fold higher SOX9 gene expression than the 10M HA 
group (p < 0.05). In comparing the LA vs. HA groups, we observed that at week 0, the 10M LA 
group had a 3.6-fold higher SOX9 expression than the 10M HA group, but at week 3 the 10M 
HA group had a 5.4-fold higher expression than 10M LA group (p < 0.05). 
 
Aggrecan:  
At week 2, the 10M HA CS and 20M HA CS groups (Figure 4.7 E&F) exhibited a 4.0-fold 
increase and 47% decrease, respectively, in aggrecan gene expression compared to week 0 (p < 
0.05), although no changes were significant at week 3. There were no other significant 
differences in expression by the CS groups at any other time point. Among the aggregate groups, 
the 20M LA group at week 3 had a 9.0-fold increase in aggrecan expression from week 0 to 
week 3 (p < 0.01). At week 3, the 20M HA group had a 54% decrease in expression from week 0 
(p < 0.05). In comparing the aggregate and respective control groups, the 10M and 20M LA 
group had a 3.0-fold higher and 2.5-fold higher aggrecan gene expression than their CS control 
groups (p < 0.05). Similarly, the aggrecan expression in the 20M HA aggregates were 8.3-fold, 
2.6-fold, and 3.1-fold higher than the respective CS control group at weeks 0, 2 and 3, 
respectively (p < 0.05).  
In comparing the 10M vs. 20M groups, we observed only one significant difference. At week 0, 
the 20M HA group had a 8.3-fold higher aggrecan gene expression than the 10M HA group (p < 
0.05). In comparing the LA vs. HA groups, we observed that there were two statistically 





expression than the 10M HA group (p < 0.05). Lastly, at week 0, the 20M HA group had a 8.6-
fold higher aggrecan gene expression than the 10M HA group (p < 0.05). The Collagen X and 
Runx2 gene expression data were not reported for the rBMSC cell line because the primers led to 
highly variable results that were not reliable in allowing for comparisons to be made, and thus 





The CS groups (Figure 4.8A) did not have any significant changes in gene expression over the 3-
week period. Among the aggregate groups, the 10M HA group had an 8.7-fold increase in 
collagen I gene expression from week 0 to week 3 (p < 0.05). The 20M LA group had a 4.0-fold 
and 5.5-fold increase in gene expression at week 2 and week 3, respectively, relative to week 0 
(p < 0.05). In addition, the 10M HA group had a 3.5-fold increase in collagen I gene expression 
from week 0 to week 3 (p < 0.05). In comparing the aggregates to their CS controls, we 
discovered only one significant difference: at week 3, the 10M LA group had a 10-fold higher 
collagen I gene expression compared to its CS control (p < 0.05). 
In comparing the 10M vs. 20M groups, we observed that at week 2, the 20M LA group had a 
2.3-fold higher collagen I expression than the 10M LA group (p < 0.05). However, at week 3, the 
10M LA group had a 3.3-fold higher collagen I gene expression than the 20M LA group (p < 
0.05). In comparing the LA vs. HA groups, it was seen that only at week 3, the 10M LA group 
had a 4.8-fold higher collagen I gene expression than 10M HA group (p < 0.05).  The 







Among the CS groups (Figure 8B), there was a 4.9-fold increase in SOX9 gene expression from 
week 0 to week 3 for the 20M LA CS group (p < 0.05). The 10M HA CS group had a 2.2-fold 
increase in SOX9 gene expression from week 2 to week 3 (p < 0.05). Among the aggregate 
groups, the 10M LA group had a 5.0-fold higher expression from week 0 to week 3, and the 20M 
LA group had a 5.6-fold expression from week 2 to week 3 (p < 0.05). In comparing the CS and 
aggregates we discovered that the 20M LA aggregates had a 2.3-fold expression at week 3, 
compared to the control group (p < 0.05). 
In comparing the 10M vs. 20M groups, the 20M LA group had a 4.2-fold and a 2.3-fold higher 
SOX9 gene expression than 10M LA group at week 2 and week 3, respectively  (p < 0.05). The 
10M HA group had a 5.8-fold and a 7.3-fold higher expression in SOX9 compared to 20M HA at 
week 2 and week 3, respectively  (p < 0.05). In comparing the LA vs. HA groups we observed 
that there were no significant difference in expression between 10M LA and 10M HA at any 
time point. However, the 20M LA group had a 5.5-fold and a 7.2-fold higher gene expression 
than the 20M HA group at week 2 and week 3, respectively (p < 0.05). 
  
Aggrecan: 
Among the CS groups (Figure 8C), the 10M LA CS group had a 5.8-fold increase in aggrecan 
gene expression only from week 0 to week 3 (p < 0.05). The other groups (10M HA CS, 20M 
LA CS, 20M HA CS) did not show any significant changes over time. Among the aggregate 
groups, the 10M HA group had a 9.3-fold increase in aggrecan expression from week 2 to week 





(p < 0.05). Finally, the 10M HA and 20M HA groups had 4.4-fold and 3.7-fold increases, 
respectively, in aggrecan gene expression from week 0 to week 3 (p < 0.05).  
In comparing the aggregate and control groups, there was only one significant difference. At 
week 3, the 20M HA group had a 2.1-fold higher aggrecan expression than its CS control (p < 
0.05). No other comparisons between the aggrecan expressions of aggregate and CS were 
statistically significant.  
In comparing the 10M vs. 20M groups, we observed that at week 2, the 10M LA group had 3.1-
fold and 2.7-fold higher aggrecan expression than the 20M LA group at weeks 2 and 3, 
respectively (p < 0.05). In contrast, for the HA groups, the 20M HA group had a 3.3-fold higher 
aggrecan gene expression than 10M HA group at week 3 (p < 0.05). In comparing the LA vs. HA 
groups, the 10M HA group had a 4.5-fold higher aggrecan gene expression than the 10M HA 
group at week 0 (p < 0.05), but no significant differences at weeks 2 or 3. The 20M HA group 
had 2.7-fold and 13.1-fold higher aggrecan gene expression than the 20M LA group at weeks 0 
and 3, respectively (p < 0.05). 
 
Collagen X: 
Among the CS groups (Figure 8D), only the 10M HA CS group displayed a significant change 
over time, with a 7.5-fold increase in collagen X gene expression from week 0 to week 3 (p < 
0.05). The other CS groups (10M HA CS, 20M LA CS, and 20M HA CS) did not display 
significant changes in expression over time. Coming to the aggregate groups, there was only one 
significant change in expression. The 10M LA group had 8.3-fold and 2.2-fold increases in 
collagen X expression from week 0 to week 2, and week 0 to week 3, respectively (p < 0.05). 





collagen X gene expression at weeks 2 and 3, respectively, compared to its CS control group (p < 
0.05). Moreover, the 20M HA group had a 3.8-fold higher collagen X expression than its CS 
control group (p < 0.05). 
In comparing the 10M and 20M groups, at week 3 alone, the 10M LA group had a 5.4-fold 
higher collagen X gene expression compared to the 20M LA group (p < 0.05). In addition, the 
20M HA group had 8.6-fold and a 2.9-fold higher collagen X gene expression compared to the 
10M HA group at weeks 0 and 3, respectively (p < 0.05). In comparing the LA vs. HA groups, 
we observed that the 10M LA group had a 5.8-fold and a 7.8-fold higher collagen X expression 
than the 10M HA group at weeks 2 and 3, respectively (p < 0.05). The 20M HA group had a 4.7-
fold and a 6.3-fold higher collagen X gene expression than the 20M LA group at weeks 0 and 2, 
respectively (p < 0.05). 
 
Runx2: 
The 10M HA CS group (Figure 4.8E) had a 2.5-fold increase in Runx2 expression from week 0 
to week 2, but no statistically significant increase at week 3 (p < 0.05). The 10M HA CS group 
had a 6.0-fold increase in Runx2 gene expression only from week 0 to week 3 (p < 0.05). Among 
the aggregate groups, the 20M HA group had a 97% decrease in Runx2 expression from week 0 
to week 3 and the 10M HA group had a 5.6-fold increase from week 0 to week 3 (p < 0.05). In 
comparing the aggregates and CS control groups, we observed only one statistically significant 
difference. At week 0, the 20M HA group had a 5.6-fold higher gene expression than its CS 
control group (p < 0.05).  
In comparing the 10M vs. 20M groups, we observed that at week 3 alone, the 10M LA group had 





groups, we observed that at week 3 alone, the 10M HA group in turn had a 3.5-fold higher 





IHC staining of the rBMSC aggregates revealed that the diameter of the aggregates decreased 
over the 3-week period, specifically the 10M HA (Figure 4.9) and 20M LA aggregates. In 
contrast, the 20M HA aggregates increased in size from week 0 to week 3. Except for the 10M 
HA group that showed increased collagen I staining at week 2 compared to week 0, collagen I 
staining did not increase with time for any other group. Collagen II and aggrecan staining were 
more intense in the 20M group for LA (especially at 2 weeks), but more intense in the 10M 
group for HA (especially at 3 weeks).  
hWJC 
Collagen I stain was prominent in the center of the aggregate for the 20M LA group at week 3 
(Figure 4.10). Collagen I did not increase in staining intensity over the 3 week period except for 
the 10M LA and 20M LA group, where the collagen I staining was highest at week 3. 20M HA 
showed highest collagen II staining at week 3. Aggrecan presented a very interesting staining 
pattern in the 10M LA and 20M HA groups, as both of these groups had starting aggrecan 
staining at week 0 to be the most intense (throughout the aggregate) and at week 3, staining was 
localized to specific patches near the center (10M LA) and around the periphery (20M HA). The 







This is the first attempt to explore the potential of hWJC aggregates, and also the first to compare 
hWJC and rBMSC aggregates with CS in the context of chondrogenesis. Cell-based approaches 
have been recently explored to regenerate several organ types, serve as a model for drug testing 
and routinely used in high throughput screening applications.
60, 112, 186, 272
 The use of stem cell 
aggregates for differentiation into the cartilage phenotype is a promising avenue for cartilage 
regeneration because of the ability to mimic mesenchymal condensation and provision of 
favorable microenvironment for cell differentiation. Hydrogel-based strategies are especially 
well poised to capitalize on these advantages by moving away from suspensions of individual 
cells to aggregate based strategies. 
Successful cell-based approaches have been reported using methods such as cell sheet 
technology, employing human embryonic stem cell aggregates and bioprinting cell-laden 
microcarriers, and have reported different results with respect to matrix biosynthesis and 
chondrogenesis.
22, 57, 68, 146
 Cell-sheet technology has broadly been used in the sense of cell-based 
approaches, although attempts are now being made to classify them into more refined ways.
74
 A 
few other groups looked into rat and mammalian stem cell aggregates, but did not employ the 
bone marrow or Wharton’s jelly cell type and the specific aggregate sizes used in the current 
study was not considered,
185, 211, 243
 as well. Our group has published several reports on hWJC 
cells for multiple applications, including chondrogenesis,
10, 167, 258
 and we are pleased to report 
that by far, the current aggregate system has produced the highest aggrecan and SOX9 gene 
expression and corresponding staining for aggrecan IHC compared to our previous studies. 
The current study further attempted to understand the influence of the number of aggregates per 





conventional CS approach (Table 4.2). Lastly, the study served as a great opportunity to compare 
the chondrogenic performance of hWJC compared to rBMSC, a well-established cell source for 
musculoskeletal tissue engineering applications.
168, 256
 Although the current study may not be 
able to conclusively prove the mechanisms by which the aggregates consistently outperformed 
the CS groups, it might be possible that the presentation of cells in a condensed manner allows 
better intercellular communication and such a high cell to cell interaction may be the basis for 
chondrogenesis. 
 
The cell viability and DNA content of all rBMSC aggregates had a higher starting DNA content 
(Figure 4.3 and 4.4) at week 0, however, at week 3, the CS and aggregate groups had comparable 
DNA content, perhaps due to a lack of adequate nutrient supply and space to proliferate. All of 
the hWJC aggregates followed a similar pattern with the aggregates having a higher starting 
DNA content compared to the CS controls at week 0, and at week 3 both groups (CS and 
aggregates) and had comparable DNA content (Figure 4.4). For the rBMSC group, both LA and 
HA groups had the same starting GAG/DNA content at week 0. But at week 3, the 20M HA 
group had a 3 fold increase compared to 20M LA suggesting that the aggregate number had an 
impact on GAG/DNA biosynthesis. However, the hWJC aggregates did not have any statistically 
significant increase in GAG biosynthesis compared to the control groups at any time point. On a 
per DNA basis for the rBMSC group, the 20M LA and 20M HA groups had the highest collagen 
content (Figure 4.6) at week 3 compared to their control groups. Taken together, findings reveal 
that on a per cell basis, both rBMSC and hWJCs did better in matrix biosynthesis and 
chondrogenesis when in aggregates than in free cell suspension. Secondly, the cell density 





20M and 10M groups did well). Moreover, the number of aggregates also mattered more for 
biosynthesis (i.e., HA outperformed LA) than for chondrogenesis. In the future, it will be 
necessary to explore which parameter values and aggregate formation methods are most 
supportive of chondrogenesis, but at least here we have demonstrated that the concept of 
aggregates to enhance chondrogenesis in hydrogels, with two different stem cell sources, is 
worth exploring, and that manipulation of parameters can impact the level of improvement. 
Some of the limitations in the current study extended to spatial and temporal control of aggregate 
placement in the agarose gels that may be addressed by a fully automated system that can direct 
aggregate placement. In the current study, agarose was used merely as a proof of concept method 
to demonstrate the impact of aggregation on cellular differentiation. In this sense, future studies 
could use cellular aggregates in conjunction with bioactive hydrogel materials such as 
functionalized poly(ethylene glycol), hyaluronic acid and other ECM-derived hydrogels to name 
a few.
17, 21, 231
 For the current study, it should also be noted that aggregates were directly 
harvested from the petri-dish and encapsulated into the agarose gels instead of chondrogenically 
inducing the aggregates. Recently, it has been reported that exposure of aggregates to 
chondroinductive media prior to encapsulation provides an extremely favorable environment for 
the aggregates to be “primed,” which drives chondrogenic differentiation.
38, 83, 217
 According to 
our data, further optimization of differentiation media, aggregate priming, and a longer duration 
of the study, will be required to achieve a molecular phenotype similar to that of a healthy 







In the current study, we successfully designed and fabricated aggregate-encapsulated agarose 
hydrogels with varied cell concentration and aggregate numbers, resulting in improved GAG 
content, DNA content, collagen content with increased gene expression of collagen II and 
aggrecan, and darker IHC staining for collagen and aggrecan compared to the CS control groups. 
Additionally, significant improvement in performance compared to the cell suspension control 
groups suggested that the aggregate approach could be a new way of looking at cells used for 
cartilage regeneration. The aggregate technique presents a simple, robust method of presenting 
cells as clusters, which, due to inherent interaction and cell-cell communication, and may prove 
to be a better choice than the conventional cell-suspension-in-hydrogel approach for cell-





CHAPTER 5: Generating Chondromimetic Mesenchymal Stem Cell 





Spheroids of mesenchymal stem cells (MSCs) in cartilage tissue engineering have been shown to 
enhance regenerative potential owing to their 3D structure. In the current study, rat bone 
marrow-derived MSCs were organized into cell spheroids by the hanging drop technique and 
subsequently cultured on hyaluronic acid (HA) coated or non-coated well plates under different 
cell media conditions. We demonstrated that for chondrogenic applications, MSC spheroids 
derived on HA-coated surfaces outperformed the non-coated spheroids in matrix synthesis and 
gene expression of chondrogenic markers. In particular, spheroids on HA-coated surfaces gave 
rise to the highest collagen and glycosaminoglycan production when primed with medium 
containing insulin-like growth factor (IGF) for a period of one week. The current study 
suggested that inductive surfaces and growth factors might influence the chondrogenesis at 
different time points suggesting the importance of a long-term study in the future. Such tailored 
bioactivity of the stem cell spheroids may give rise to a platform technology that may eventually 
produce spheroids capable of chondrogenesis achieved by surface coating and media 
manipulation over time.  
 
                                                 
4
 Under preparation as Sridharan B., Laflin AD., Detamore M.S., “Generating Chondromimetic Mesenchymal 







Autologous chondrocytes are a limited resource due to donor site availability, tissue morbidity, 
and waiting period for expansion in culture. Several studies have illustrated the promise that 
multipotential mesenchymal stem cells (MSCs) hold for chondrogenesis, osteogenesis, 
adipogenesis and other musculoskeletal applications, including current clinical trials.
13, 120, 137, 198
 
Often the regenerative benefits are lost after successive passaging and expansion of cells in vitro, 
which relies on culturing them a non-physiologic monolayer.
189, 226
 3D culture overcomes some 
of the limitations presented by the monolayer culture system. For example, assembly of MSCs as 
cell spheroids by the pellet culture technique has long been employed for increasing the 
chondrogenic potential under in vitro conditions.
6, 265, 270
 Forming 3D cell spheroids by the 
conventional hanging drop method has been suggested as a means to enhance the therapeutic 
potential and has been shown to elicit anti-inflammatory effect of MSCs.
14, 15, 136, 269
 Recent 
reports have demonstrated that the use of MSC spheroids formed by hanging drop or suspension 
culture enhanced their therapeutic potential for cartilage regeneration in vivo.
80, 136, 163
 Similarly, 
growing MSCs on surfaces with different surface stiffness have also yielded viable spheroids 
with great stemness and differentiation capabilities.
139, 153, 253
 
Hyaluronic acid (HA) is a linear anionic polysaccharide composed of long chains of repeating 
disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine.
76, 244
 In cartilage 
extracellular matrix (ECM), HA is the backbone of aggrecan superstructure complexes,
32
 and it 





we explored the potential of HA as a surface coating agent to evaluate its impact on MSC 
spheroid differentiation. 
We hypothesized that MSCs that were formed into 3D spheroids, cultured in HA-coated well-
plates and primed under different medium compositions would exhibit increased survival and 
chondrogenic gene expression compared to spheroids in control medium under non-coated 
conditions. To test this hypothesis, we examined the chondrogenic potential of MSC spheroids 
that were first subjected to either HA-coated or non-coated conditions. To further explore the 
influence of raw materials and growth factor under culture conditions, the spheroids were 
subjected to serum-rich or serum free medium with either transforming growth factor (TGF)-β3, 
insulin-like growth factor (IGF)-1, chondroitin sulfate (CS), and aggrecan. Lastly, an additional 
group was added where the medium was changed from TGF-β3  to IGF-1 after 3 days of culture 
(TGF ⇒ IGF). The experimental group and controls were tested for cell viability and 
chondrogenic applications through gene expression, immunohistochemistry and matrix content. 
 
MATERIALS AND METHODS 
Cell culture and expansion 
Rat bone marrow-derived mesenchymal stem cells (rBMSCs) were harvested from the femurs of 
seven young male Sprague–Dawley rats (176–200 g, Charles River) following a University of 
Kansas approved IACUC protocol (175–08). The IACUC protocol approved the cellular harvest 
procedure and usage of cells for this particular study. The cells were isolated according to a 
previously reported protocol.
169
 Briefly, isolated cells were cultured in control medium (αMEM 





Life Technologies, Carlsbad, CA) and passaged at 80% confluence until passage 4 (P4). As 
reported earlier, all of the cells from 14 different femurs were pooled together at P4 for use in the 
study.  
 
Preparation of HA-coated well plates 
HA sodium salt of medical grade (Lifecore Biomedical, Chaska, MN, USA) was obtained as a 
dry powder. According to the information from the supplier, the HA molecular weight was 
between 200-350 kDa. Well plates were coated with HA according to a previously reported 
protocol.
139
 Briefly, polylysine-coated 96-well plates (Sigma-Aldrich) were cleaned 
ultrasonically in acetone and then rinsed with ethanol. A deionized water rinse was used to 
remove liquid chemicals followed by a nitrogen purge. 300 μL of 1 mg/mL aqueous solution of 
HA was pipetted into a single well of a 96-well plate and air-dried in a sterile environment for 
3 days at 25 °C to prepare the HA-coated surfaces. 
 
Cellular aggregate formation 
Spheroids were generated by the hanging drop technique according to a previously reported 
protocol.
15, 267
 Cellular suspensions (rBMSC) were prepared at concentration of 10×10
6
 cells/mL 
in medium. Droplets of cell suspensions (cells with corresponding medium, see below) at a 
volume of 10 μL were pipetted onto the inside surface of a sterile petri dish lid in an array using 
a 10 μL pipette (Eppendorf, Hauppauge, NY), making sure that the droplets have a safe distance 
between each other to prevent mixing. The cells were allowed to aggregate overnight, with the 
help of gravity when the petri dish lid was reversed (Fig. 1). The sterile petri dish bottom was 





collected from the dish with the help of a 1 mL pipette and placed into well plates (1 spheroid 
per well) and cultured in the same medium composition in which the spheroids were formed.  
Spheroids were created in one of six different types of medium, including control medium, and 
then placed on either a coated or non-coated surface, where the spheroids then continued in the 
same medium in which they were formed (Fig. 1). The one exception was the TGF/IGF group, 
where spheroids were formed in TGF medium, then cultured in TGF medium for 3 days before 
being switched to a different medium (i.e., IGF medium). The spheroids were harvested after 24 
h, and were either processed directly for different assays (i.e., the week 0, or “hanging drop” 
time point), or placed in well plates for additional culture. In the well plates, one set of spheroids 
were placed in HA-coated well plates, where the medium was changed every other day and 
samples were collected at 24 h and 7 days (to evaluate changes over time for the experimental 
coating surface). The other set of spheroids were placed under regular 96 well plates that were 
not coated with HA, where the medium was changed every other day and samples were collected 
at 7 days (providing a control surface comparison for the experimental coating surface at the 
final time point).  
The six medium groups used for aggregate formation and culture were as follows (Fig. 1): 
Control group: The control medium consisted of αMEM, 10% FBS and 1% Pen-Strep. 
TGF group: TGF medium consisted of low glucose DMEM, 1% Pen-Strep, and 5 ng/mL TGF-
β3  (PeproTech, Rocky Hill, NJ).  
IGF group: IGF medium consisted of low glucose DMEM, 1% Pen-Strep, and 100 ng/mL IGF-
1 (PeproTech, Rocky Hill, NJ).  
CS group: CS medium consisted of low glucose DMEM, 1% Pen-Strep, and 40 μg/mL CS 





Aggrecan group: Aggrecan medium consisted of low glucose DMEM, 1% Pen-Strep, and 40 
μg/mL aggrecan (Catalog number: A1960, Sigma-Aldrich). 
TGF ⇒ IGF group: Spheroids were formed in TGF medium, and then conditioned with the 
TGF medium in well plates for the first 3 days. After medium removal at the end of day 3, IGF 
was added to the spheroids for 4 additional days. Given that this group was identical to the TGF 
group at the hanging drop and 24 h time points, only the 7 day time point was run for this group 
(only coated). 
 
Cell viability assay 
To check the viability of the spheroids, a fluorescent live/dead viability staining kit (Invitrogen, 
Carlsbad, CA) was used at day 0 and 7 days. The samples (n = 3) were washed once with 
phosphate-buffered saline (PBS) and incubated in live/dead staining solution (0.5 µL calcein 
and 2.0 µL ethidium homodimer (ETH) diluted in 1 mL PBS) for 10 min (37C, 5% CO2). The 
samples were once again washed with PBS prior to imaging using an inverted epifluorescent 




Spheroids were placed in a papain digestion solution consisting of 125 mg/mL papain, 5 mL N-
acetyl cysteine, 5 mL ethylenediaminetetraacetic acid and 100 mL PBS (all reagents from 
Sigma-Aldrich, St. Louis, MO) in distilled water overnight in a 60C water bath. On the 
following day, sample digests (n = 5) were centrifuged for 5 minutes and stored at -20 C until 





technologies) according to the manufacturer’s instructions. Previous studies from our group 
(unpublished) established a conversion factor of 7.7 pg/cell that may be used to convert DNA 
content to cell number. 
 
Glycosaminoglycan assay 
Spheroids (n = 5) were digested with the aforementioned papain digesting solution and left in a 
60C water bath overnight prior to measuring glycosaminoglycan (GAG) content. GAG content 
was measured with a Sircol DMMB assay kit and the manufacturer’s protocol (Biocolor B1000, 
Belfast, U.K.) was followed. 1.0 mL of dimethylmethylene blue dye solution was added to 100 
µL of sample, standards provided in the kit (Chondroitin sulfate, Sigma-Aldrich), and blank. 
Solutions were mixed slowly for 30 minutes and centrifuged for 10 minutes. The supernatant 
was discarded and the pellet was resuspended, and 1.0 mL of dissociation solution was added. 




For quantifying collagen production, a Sircol soluble collagen assay kit and manufacturer’s 
protocol were used (Biocolor, s5000, Belfast, U.K.). Briefly, samples (n = 4) were incubated in 
.1 mg/mL pepsin in 0.5 M acetic acid (Sigma-Aldrich P7012)  and placed overnight at 4C. 1.0 
mL of Sircol dye reagent and 100 µL of each standard (collagen standards provided by the 
manufacturer) and sample were mixed slowly for 30 minutes. Solutions were centrifuged at 
12,000 rpm for 10 minutes and the resulting supernatant discarded, keeping the pellet intact. The 





resuspended and to this 250 µL of alkali reagent was added. Solutions were then vortexed 
thoroughly and 200 µL of the solution was transferred to a 96-well plate and ran at 555 nm in a 
microplate reader.  
 
Gene expression analysis 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was used to assess gene 
expression levels for collagen types I, II, SOX9, and aggrecan (n = 5). To each sample 1.0 mL of 
lysis buffer (Qiagen, Germantown, MD) was added, and after 1 hour, the solutions were passed 
through a QIAshredder column (Qiagen 79656, Germantown, MD) to extract messenger RNA 
(mRNA) in accordance with the RNEasy Plus Mini Handbook (Qiagen 74136, Germantown, 
MD) (n = 4). A high capacity cDNA reverse transcription kit (Applied Biosystems 4368814, 
Foster City, CA) allowed reverse transcription of mRNA to complementary DNA (cDNA); 2x 
RT Master Mix was prepared using the kit’s protocol. 10 µL of the master mix and RNA 
samples were combined in a 96-well plate. The well plate was then loaded into an Eppendorf 
Realplex Mastercycle (Eppendorff, 5345 Hauppauge, NY). cDNA concentrations were 
normalized with DNASE-free water, and a Taqman gene expression assay kit (Applied 
Biosystems 1325810, Foster City, CA) provided the primers for the above-mentioned genes. 1 µl 
of cDNA from each sample, 10 µl of universal fast master mix (2x), and 1 µL of a specific 










Spheroids were fixed, cleared in xylene, dehydrated and embedded in paraffin blocks until 
further use. The sections were generated using a microtome and sectioned to a thickness of 4 µm. 
Sections (n = 3) were immersed in xylene; rehydrated in graded ethanol and rehydrated in 
deionized water for 5 minutes (all reagents from Sigma-Aldrich). The sections were exposed to 
3% hydrogen peroxide in methanol for 10 minutes to suppress endogenous peroxidase activity 
and immediately the slides were incubated in proteinase K (IHCWORLD IW-1101, Woodstock, 
MD) at 37C for 10 minutes. Sections were blocked with 3% blocking serum (Vector 
Laboratories S-2012, Burlingame, CA) for 30 minutes preceding primary antibody/ isotype (IgG) 
control antibodies incubation for collagen I, collagen II, and aggrecan for 60 minutes (Table 3). 
Following primary antibody incubation, slides were exposed to biotinylated secondary antibody 
and ABC reagent (Vectastain ABC kit PK-6200 Vector laboratories) for 30 minutes each. Lastly, 
the ABC reagent was added to the sections after washing with PBS and incubated for 30 minutes 
and then washed again. Tissue staining was accomplished with ImmPact DAB peroxidase 
substrate (Vector laboratories SK-4105) before rinsing with distilled water and counter stained 
with VECTOR hematoxylin QS stain (Vector laboratories H-3404). Following staining, slides 
were rinsed in tap water; dehydrated in ethanol; cleared in xylene for mounting (Permount SP15-
500 Fair Lawn, NJ) and viewed under an upright microscope (Zeiss, Imager A2). 
 
Statistical analyses 
All data were expressed as mean ± standard deviation. Statistical analyses were performed using 
one-way ANOVA (Minitab 15, Minitab Incorporated, State College, PA) followed by a Tukey’s 
post hoc comparison test for repeated measurements. The statistical significance threshold was 








Cell viability assay 
Cell viability was high overall for the spheroids that were isolated right after the hanging drop 
procedure (Fig. 2). When the spheroids were placed in HA-coated plates, there was an apparent 
decrease in spheroid diameter. By 7 days, the coated groups had roughly half the cell viability for 
the aggrecan, IGF, and the TGF ⇒ IGF group. In fact, the IGF and CS groups lost their spherical 
shape and only spheroid fragments were stained. Similarly, in the 7-day non-coated groups, only 
the TGF group maintained its spherical morphology. The control medium group (10% FBS) 
completely disintegrated, and the spheroids in the aggrecan and CS group were disintegrated. 
 
DNA Content 
Within each given medium group, DNA content differences over time were statistically 
significant between the hanging drop time point (Fig. 3) (i.e., t = 0, prior to placing on any 
surface) and the 7 day time points, for both the coated and uncoated surfaces. The control 
medium group DNA content dropped by 43.7% and 61.4% from t = 0 to day 7 for the coated and 
non-coated surfaces, respectively (p < 0.05). The TGF group DNA content dropped by 40.6% 
and 44.9% from t = 0 to day 7 for the coated and non-coated surfaces, respectively (p < 0.05). 
The IGF group DNA content dropped by 56.4% and 95.3% from t = 0 to day 7 for the coated and 
non-coated surfaces, respectively (p < 0.05). The CS group DNA content dropped by 97.2% and 
84.5% lower DNA content from t = 0 to day 7 for the coated and non-coated surfaces, 
respectively (p < 0.05).  
The aggrecan group DNA content dropped by 81.7% and 32.6% from t = 0 to day 7 for the 





dropped by 93.2% from t = 0 to day 7 for the coated surface (p < 0.05). No statistically 
significant differences in DNA content were noted among groups at t = 0, 24 h or on either 
surface at 7 days.  
 
GAG content 
Statistically significant increases in GAG/DNA content were observed in all six groups 
(including control) for both surfaces by 7 days, but only the control group had a significant 
increase by the 24 hour time point. The control medium group had 5.0-fold and 6.8-fold 
increases in GAG/DNA content (Fig. 4) from t = 0 to 24 h and 7 days on the non-coated surface, 
respectively (p < 0.05). The TGF group had 2.7-fold and 2.4-fold increases in GAG/DNA 
content from t = 0 to day 7 for the coated and non-coated surfaces, respectively (p < 0.05). The 
IGF group had a 9.3-fold increases in GAG/DNA content from t = 0 to day 7 for non-coated 
surface (p < 0.05). The CS group had 3.3-fold and 7.5-fold increases in GAG/DNA content from 
t = 0 to day 7 for coated and non-coated surface, respectively (p < 0.05). The aggrecan group had 
3.4-fold and 1.4-fold increases in GAG/DNA content from t = 0 to day 7 for the coated and non-
coated surfaces, respectively (p < 0.05). Among the groups on the HA-coated surface at day 7, 
the TGF and IGF groups had 1.6 and 1.1 times higher GAG/DNA contents compared to the 
control group, respectively (p < 0.05), with no other statistically significant differences. Finally, 
the aggrecan group had a 23.5% lower GAG/DNA content from t = 0 to day 7 for non-coated 
surface (p < 0.05).  
 
Collagen content 
There were no statistically significant increases in collagan content for any group from the 





were noted by 7 days. First, the control group had 5.3-fold and 5.1-fold increases in 
collagen/DNA content (Fig. 5) from t = 0 to day 7 for the coated and non-coated surfaces, 
respectively (p < 0.05). The TGF group had a 6.3-fold increase in collagen/DNA content from t 
= 0 to day 7 for the coated surface (p < 0.05). The IGF group had 11.7-fold and 26.1-fold 
increases in collagen/DNA content from t = 0 to day 7 for the coated and non-coated surfaces, 
respectively (p < 0.05). The CS group had 16.5-fold and 11.8-fold increases in collagen/DNA 
content from t = 0 to day 7 for the coated and non-coated surfaces, respectively (p < 0.05). The 
aggrecan group had a 2.7-fold increase in collagen/DNA content from t = 0 to day 7 for the non-
coated surface (p < 0.05). Finally, the TGF⇒ IGF group had a 13.9-fold increase in 
collagen/DNA content from t = 0 to day 7 for the coated surface (p < 0.05). In comparing the 
collagen/DNA values between the control group and each of the other groups at the same time 
point, there were two statistically significant differences. At day 7 on the coated surface, the CS 
group had a 3.3-fold higher collagen/DNA content than the control group (p < 0.05). At day 7 on 
the non-coated surface, the IGF group had a 6.7-fold higher collagen/DNA content compared to 
the control media group (p < 0.05).  
 
Gene expression analysis 
 
Aggrecan: 
There was no statistically significant change in aggrecan gene expression (Fig. 7) for the control 
group over time. Coming to the TGF group, there were 23.4%, 68.9%, and 37.4% decreases in 
aggrecan gene expression from t = 0 to 24 h and day 7 for the coated and non-coated surfaces, 
respectively (p < 0.05). For the IGF group, there were 35.6%, 85.4% and 98.5% decreases in 





respectively (p < 0.05). The CS group had 76.4%, 79.2%, and 71.3% decreases in gene 
expression from t = 0 to 24 h and day 7 for the coated and non-coated surfaces, respectively (p < 
0.05). The aggrecan group also had decreases of 45.7%, 38.4%, and 54.4% in aggrecan gene 
expression from t = 0 to 24 h and day 7 for the coated and non-coated surfaces, respectively (p < 
0.05). The TGF⇒IGF group alone had a 1.55-fold higher aggrecan gene expression from t = 0 to 
day 7 coated surface (p < 0.05).  
 
In comparing between the groups at the same time point, we observed that at t = 0, all of the 
medium compositions had a significantly higher aggrecan gene expression than the control 
group. However, there were no significant differences in gene expression between the control 
group and other groups at 24 h or at day 7 on the coated surface. For the t = 0 time point and day 
7 non-coated surface, there was a 3.8-fold higher aggrecan gene expression for the TGF group 
and a 3.7-fold higher expression for the aggrecan group, (p < 0.05). 
 
SOX-9: 
The control group had a 2.9-fold higher SOX-9 gene expression from t = 0 to 24 h for the coated 
surface (p < 0.05). There was no statistically significant difference in SOX-9 expression over 
time for the TGF group. The IGF group had a 8.6-fold higher gene expression from t = 0 to day 7 
for the non-coated surface (p < 0.05). The CS group on the other hand had a 11.2-fold, 6.4-fold, 
and 5.5-fold higher SOX9 gene expression from t = 0 to 24 h coated and day 7 for the coated and 
non-coated surfaces, respectively (p < 0.05). The TGF⇒IGF group had a 11.1-fold higher SOX-






In comparing the different media compositions at the same time point, we observed that the CS 
group had a 6.5-fold higher expression at t = 0, compared to the control media group (p < 0.05). 
The CS group also had a 7.3-fold higher expression at t=0 compared to the control media group 
(p < 0.05). The IGF group had a 4.8-fold higher expression for the 24 h coated surface compared 
to the control group (p < 0.05). Lastly, the aggrecan medium at day 7 non-coated surface had a 
7.1-fold higher gene expression compared to the control media group (p < 0.05). 
 
Collagen II: 
The control, IGF, and TGF⇒IGF groups did not have a significant change in gene expression 
over the 7 day time period. The TGF group had a 3.1-fold higher gene expression only from t = 0 
to day 7 non-coated surface (p < 0.05) and not at any other time point. The CS group had a 10.6-
fold higher collagen II gene expression from t = 0 to day 7 non-coated surface (p < 0.05). The 
aggrecan group had a 4.3-fold higher collagen II gene expression from t = 0 to 24 h coated 
surface (p < 0.05). 
 
In comparing between the different media groups at the same time point we observed that all the 
media groups had a significantly higher gene expression compared to the control media group at 
the t=0 time point. There was no significant difference for the 24 h coated surface for any media 
groups. Coming to the 7 days coated surface, the TGF, IGF, CS, and aggrecan group had a 0.7-
fold, 0.5-fold and 0.4-fold lower collagen II gene expression compared to the control media 
group (p < 0.05). At the 7 day non-coated surface, only the CS group had a 6.8-fold higher 







The control media group had 2.7-fold, 2.1-fold and 1.9-fold higher collagen I gene expressions 
from t = 0 to 24 h coated and day 7 for the coated and non-coated surfaces, respectively (p < 
0.05). The TGF group had a 15. 6% and 42.8% decrease in collagen I gene expressions from t = 
0 to 24 h coated and day 7 non-coated surfaces, respectively (p < 0.05). The IGF group had a 
3.2-fold higher expression from t = 0 to day 7 coated surface, respectively (p < 0.05). It also had 
a 34.7% lower gene expression from t = 0 to day 7 non-coated group (p < 0.05). The CS group 
had 23.6% and 56.8% lower gene expressions from t = 0 to day 7 coated and non-coated 
surfaces, respectively (p < 0.05). The aggrecan group had 38.5% and 67.2% lower gene 
expression from t = 0 to day 7 coated and non-coated surfaces, respectively (p < 0.05). 
In comparing the difference in expression between different media groups over the same time 
point we observed that the all the media groups (TGF, IGF, CS, aggrecan, and TGF⇒IGF) had a 
significant difference compared to the control media groups for the 24 h coated, day 7 coated and 
non-coated groups (p < 0.05). 
 
Immunohistochemistry 
IHC staining of the control media spheroids revealed that the diameter of the spheroids decreased 
over the one-week period, specifically from the hanging drop time point to the 7 day time point 
on the non-coated surface. Figure 7a represents the collagen I immunostaining for representative 
groups. The hanging drop time point showed the highest collagen I staining intensity followed by 
the CS and TGF groups at 24 h. The 7 day HA-coated (TGF) aggregate started to show 
disintegration and the 7 day HA-coated IGF showed complete degradation in spheroid 





diameter apparently decreased from hanging drop group to the 24 h coated group. The hanging 
drop group with CS medium showed highly intense staining for collagen II compared to the TGF 
and aggrecan medium. Figure 7c shows aggrecan immunostaining for representative groups. 
TGF primed medium stained after hanging drop and after 24 h in coated plate showed intense 
aggrecan staining. Though the 24 h coated control media primed spheroid showed negligible 
staining, by day 7 it stained intensely throughout the spheroid. 
 
DISCUSSION 
MSCs are a promising source for cell-based therapies because of their multipotent regenerative 
capabilities. One way of exploiting MSCs is organizing them into 3D stem cell spheroids or 
spheroids that have shown good regeneration and anti-inflammatory properties. Spheroids have 
recently shown to be more effective than single cells for defect filling and better cartilage 
regeneration.
108, 142 
Previous in vitro studies have shown that microenvironment and surface stiffness plays an 
important role in shaping the cell migration and eventual differentiation of the MSC spheroids.
12, 
153
 Specifically, HA is a commonly explored chondroinductive ECM component used both as a 
surface and as a scaffolding agent.
33, 129
 Other studies have looked into using HA to coat well-
plates where the molecular weight of the HA alters the stiffness.
139, 140
 For the current study, we 
used a Mw of 360 kDa that accounted for intermediate range of stiffness. Compared to the 
previous studies, we have for the first time use MSC spheroids of this cell density directed at 
chondrogenic applications. The effect of HA can clearly been seen in the GAG and collagen 
content of the spheroids, however the long-term effects cannot be elucidated from the current 





and collagen content compared to the hanging drop group. Although the average size of the 
spheroids varied among the groups, from live-dead assay (Figure 2) we can infer that the 
spheroids harvested from the hanging drop petri dishes possessed the highest diameter compared 
to the spheroids after 24 h and 7 day culture. Due to a shortage of cells, we prioritized on the 
HA-coated group and did not include the 24 h non-coated group for the current study. The 
significant difference in the properties of the spheroids thus seemed to be associated with the 
overall spheroid size that will need further exploration. Furthermore, other polymers apart from 
HA such as chitosan, alginate, poly ethylene glycol with different molecular weights may yield 
exciting results on how surface stiffness affects differentiation. 
New medium recipes are constantly being explored to enable provision of the best culture 
conditions for cellular differentiation. In particular, growth factors and bioactive peptides as 
medium supplements are being extensively researched for musculoskeletal applications.
131, 193, 264
 
Several studies have shown the therapeutic advantages of using TGF in the medium composition 




 During the 
last decade, IGF had also gained a lot of interest as it has shown to be misregulated playing an 
anabolic role in cartilage degeneration.
174, 234
 Several approaches have thus employed IGF in 
their scaffold design and the media composition for regenerating cartilage.
119, 254, 255
 In 
comparing the results from the current study to previously published studies from our lab, we 
observed that for the same cell density, spheroids primed under IGF medium surpassed all other 
previous SOX9 and collagen I gene expression.
254
 At the hanging drop time point, the DNA 
content of the IGF group was higher than what we have seen so far
255
, thus reiterating the 
importance of cellular presentation as three-dimensional spheroids compared to cellular 





spheroids were primed with TGF the first three days and changed to IGF for the last 4 days. This 
additional group was specifically included to observe the effect of IGF on late stage 
differentiation, as observed before.
255
 The IGF medium primed 7 day non-coated group, 
exhibited the highest GAG/DNA content. Although several groups have explored IGF for 
chondrogenesis,
52, 160
 this is the first time that IGF has been tested as a priming formulation for 
use in stem cell spheroids. One of the main directions of our lab has been to explore the 
chondroinductive properties of raw materials, and so far we have assessed raw materials like 
aggrecan, CS, decellularized cartilage, bioactive glass in scaffold fabrication. To take it one step 
further, in the current study we directly added CS and aggrecan in the medium at concentrations 
reported favorably earlier.
100, 117
 Although the concentrations are different under in vivo 
conditions, premature priming of the spheroids to raw materials may preemptively induce GAG 
and collagen production that can be complemented when placed in the body. In the current study, 
we found that the CS medium primed at the hanging drop stage showed the highest SOX-9 gene 
expression and at 7 days non-coated conditions showed the highest collagen II expression. This 
is an important implication as it opens a new path to look at medium formulations as raw 
materials so far are exclusively used only for scaffold fabrication. If the addition of CS in 
medium could yield comparable results with that of growth factors, it is an easy and efficient 
approach from a financial and federal regulation standpoint and cannot be ignored for future 
applications. Although there has been several studies that have independently explored surface 
stiffness on spheroid properties, and others that have looked into different media formulations, 
there is a complete lack of approaches that employ conjointly explore both the parameters on 
spheroid differentiation. 





when it comes for clinical applications is the time required for spheroid formation. Secondly, 
there was a genuine attempt to vigorously perform immunohistochemistry testing for all the 
groups but the spheroids are extremely small after one week of culture and in many cases 
disintegrated and hence lost in sample processing. Future studies that focus on better spheroid 
retention in paraffin molds and look at the regeneration from a different testing paradigm may 
benefit the entire field. Finally, one week is too short a time to evaluate cartilage regeneration. 
The experiment presented here only serves as a preliminary in vitro approach to support the 
different capacities of the spheroids subjected to different surface stiffness and medium 
compositions. 
Upon establishment of the benefits of spheroid priming, future studies could look at other media 
raw material/growth factor combination to find a winning formulation for cartilage-like tissue 
spheroids. The next step along the way is spheroid implantation into animal models and 




In the current study, we successfully primed the spheroids under different medium conditions 
with exposure to HA coated or non-coated well plates and observed the chondrogenesis of the 
spheroids. We observed that exposure to HA-coated well plates resulted in overall retention of 
spherical morphology and increased viability compared to the non-coated groups. Moreover, the 
hanging drop time point demonstrated a high cell viability and aggrecan gene expression 
compared to the other time points. Additionally, raw materials (i.e., CS and aggrecan) alone had 





primed groups suggesting that raw material addition in the medium could be a new economic 
and efficient way of looking at medium formulation for chondrogenic applications. The priming 
exercise gave new insights in to 3D spheroid behavior under a diverse microenvironment, 
suggesting the close interplay between surface modification and medium composition. The 
consideration of control media spheroids, exclusion of serum and growth factors and inclusion of 
raw materials in the medium may be a promising path to generate chondromimetic tissue for 












To date, many osteochondral regenerative approaches have utilized varying combinations of 
biocompatible materials and cells to engineer cartilage. Even in cell-based approaches, to date, no 
study has utilized stem cell aggregates alone for regenerating articular cartilage. The purpose of 
this study was thus to evaluate the performance of a novel stem cell-based aggregate approach in 
a fibrin carrier to regenerate osteochondral defects in the Sprague-Dawley rat trochlear groove 
model. Two different densities of rat bone marrow mesenchymal stem cell (rBMSC) aggregates 
were fabricated by the hanging drop technique. At 8 weeks, the cell aggregates supported the 
defects and served as a catalyst for neo-cartilage synthesis, and the experimental groups may have 
been beneficial for bone and cartilage regeneration compared to the fibrin-only control and sham 
groups, as evidenced by histology. The cell density of rBMSC aggregates may thus directly 
impact chondrogenesis. The usage of cell aggregates with fibrin as a cell-based technology is a 
promising and translational new treatment strategy for defect repair of cartilage defects. 
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In the United States, trauma-related cartilage damage and aging-related cartilage degeneration 
alone have cost several millions of dollars.
26, 31, 235
 There is thus an unmet need to develop 
substantial cost-effective treatments for osteoarthritis. Over the last couple of decades, numerous 
strategies have been developed in an effort to regenerate the osteochondral interface
73, 156, 180, 201
 
that employ autologous cell suspensions of either differentiated chondrocytes or undifferentiated 
bone marrow-derived mesenchymal stem cells (BMSCs).
37, 149
 Several review papers discuss 
various types of cell-based approaches and the relative advantages they impose compared to 
other material-based strategies.
67, 198, 237
 Despite the success of cell-based techniques, clinical 
outcomes are significantly affected by the formation of fibrocartilage after long-term 
implantation, thus requiring multiple surgeries that in turn may give rise to donor site morbidity 
and increase the overall cost of healthcare.
122, 179
 To overcome the above listed disadvantages, 
investigators have resorted to employing cells in combination with biocompatible natural 
materials such as alginate, agarose, collagen, and silk fibroin, and polymers such as polylactic-
co-glycolic acid, polyglycolic acid, and polycaprolactone, which under certain fabrication 
conditions may possess mechanical properties similar to the native cartilage.
17, 66
 However, a 
cell-based system based on both natural materials and cells may hold advantages in quality of 
regeneration, although translational limitations must be overcome. 
 
While there have been several advances for in vivo approaches for cartilage tissue engineering 
using cell-based strategies, the number of cell aggregate approaches are limited.
154, 207, 218, 219
 Cell 







cell contact. Commonly, aggregates have been explored for pancreatic islet regeneration, 
targeted drug delivery approaches for cancer therapy, and in general they serve as a great three-
dimensional cellular model for drug testing.
86, 106, 127, 271
 Translating the aggregate technology to 




Looking at material-based approaches in rat models, a steady number of studies use external 
chemical stimuli such as raw materials, growth factors and other bioactive molecules in their 
scaffolds. In this regard, transforming growth factors (TGFs) and bone morphogenetic proteins 
(BMPs) have been shown to stimulate stem cell differentiation into cartilage and bone, 
respectively. Specifically, TGF-β1 and TGF-β3 are known to promote chondrogenesis and BMP-
2 and BMP-7 are known to promote osteogenesis.
25, 85, 190
 While the addition of these external 
stimuli may lead to quality tissue regeneration, it can be quite expensive, may have side effects, 
and lead to a more involved regulatory process. Cellular aggregates employed in the current 
study, however, provide a more translational approach by exploiting known intercellular 
communication from cell pellet cultures in chondrogenesis as an inherent cue to differentiate 
MSCs toward the cartilage phenotype. Based on a rationale of potentially possessing a greater 
extent of intercellular communication, our hypothesis was that within 8 weeks, dense cellular 
aggregate group would outperform the fibrin group and sham surgeries in histological and gross 
morphological assessment. 
  
Small animal model such as rodents are considered valid as proof of concept and preliminary 
research models.
2, 49







fibrin for articular cartilage regeneration, a critical sized defect of the trochlear groove was 
selected as a reasonable defect area based on established precedent in the literature.
49, 138, 246
 The 
current study investigated cartilage regeneration in a critical sized trochlear groove defect in 
Sprague-Dawley rats with cell aggregates of different densities, and compared the performance 
with a fibrin-only control group and a sham negative control. The induced defect size was 
approximately 2.0 mm in diameter and 2.0 mm in depth. Regeneration was evaluated at 8 weeks 
with gross morphological scoring and histological staining. The goal of this pilot study was to 
determine whether the cell aggregates would facilitate neo-cartilage formation in the rat trochlear 
groove as a foundation for future in vivo studies. 
 
MATERIALS AND METHODS 
Cell harvest and culture 
Rat bone marrow-derived mesenchymal stem cells (rBMSC) were harvested from the femurs of 
five young male Sprague–Dawley rats (200–250 g, Charles River) following a University of 
Kansas approved IACUC protocol (175–08). The IACUC approved the use of rBMSC cells for 
use in this particular study. The cells were isolated according to our previously reported 
protocol.
9, 239
 Briefly, isolated cells were cultured in rBMSC media (αMEM supplemented with 
10% MSC-qualified FBS and 1% Penicillin-Streptomycin (Invitrogen Life Technologies, 
Carlsbad, CA)), and passaged at 80% confluence until P4. All cells from different femurs were 








Cellular aggregate preparation 
Aggregates for the current study were generated by the hanging drop technique.
243, 267
 Cellular 





 cells/mL, in rBMSC media. The cellular concentration was confirmed using a 
Cellometer automatic T4 cell viability counter (Nexcelcom Bioscience, Lawrence, MA). 
Droplets of cell suspensions at a controlled volume of 10 μL that had 10,000 or 20,000 cells were 
pipetted in an array onto the inside surface of a sterile petri dish lid using a 10 μL pipette 
(Eppendorf, Hauppauge, NY), making sure that the droplets had a safe distance between each 
other to prevent mixing. The cells were allowed to aggregate overnight, aided by gravity when 
the petri dish was reversed. The sterile petri dish bottom was then filled with sterile PBS to 
prevent drying of these droplets. After 24 hours, the cell aggregates were carefully collected 
from the dish with a 1 mL pipette and collected in Eppendorf tubes for the study. Aggregates 
were placed in defects within 3 hours of harvest, as noted below. 
Description of Experimental Groups 
Four different treatment groups were investigated: (i) Group A, where the defect was created and 
filled with 75 rBMSC aggregates, each with a cell density of 10 million/mL (note: density based 
on volume of initial 10 μL suspension), (ii) Group B, where the defect was created and filled 
with 75 rBMSC aggregates each with cell density of 20 million/mL, (iii) Sham surgeries, in 
which a defect was created, but no implant was placed and, (iv) Fibrin groups where the defect 







petri-dish used to make the hanging drop aggregates had exactly 75 drops and care was taken to 
harvest all of the aggregates, thus making sure we had 75 aggregates for each knee. 
Surgical Procedure 
Surgical procedures were conducted under an approved IACUC protocol at the University of 
Kansas (Animal Use Statement #175-20), utilizing a total of 10 male Sprague Dawley rats (200-
250 g, Charles River). The IACUC approved the protocol to be used for this particular study. 
Following stable general anesthesia, hair was shaved from the area around each rat knee. The 
knee was then disinfected with three alternate scrubs of Betadine and 70% ethanol, and then 
draped so as to expose only the knee area. Care was taken to use only strict aseptic techniques 
and sterile instruments, and the surgeon wore sterile gowns, masks, and head covers. All surgical 
tools, including drill and stoppers, were sterilized prior to surgery. A midline knee incision was 
made for an intra-articular lateral parapatellar arthrotomy sufficient enough to allow exposure of 
the trochlear groove. The defect was drilled to a depth of 2.0 mm depth and 2.0 mm diameter 
using a drill with a stopper attached to the bit. Defects were then filled with either the aggregate 
groups (Group A or B), or fibrin (Tisseel ®, Baxter, Deerfield, IL) (Fig. 6.1). The aggregates 
were harvested 3 hours before the surgery, as noted in the ‘Cellular aggregate preparation’ 
subsection above, and immersed in rBMSC media until implantation. At the time of 
implantation, aggregates were carefully pipetted into the defect area. Sham defects were created, 
in which a hole was drilled, but no implant was placed. Following implantation of the aggregate 
groups, 50 μL of fibrin was added on top of the aggregates to seal the clot with the surrounding 
tissue. Although 6 μL was enough to cover the defect, a little extra fibrin was added to secure the 







minutes. The joint was then washed with sterile pharmaceutical grade saline water and the bursae 
was closed with absorbable suture. The skin was then closed with polysorb 3.0, a non-absorbable 
suture. The procedure was followed on the contralateral knee with a different group to ensure 
independence of knees within groups (Fig. 6.2). After the surgery was completed, the rats were 
administered carprofen subcutaneously, and returned to be caged individually. The knee joints 
were allowed unconstrained movement postoperatively. 
Post-surgical Care 
The rats were continuously monitored for the first three days and any signs of limping or unease 
was treated with carprofen injection administered subcutaneously only once a day. Three rats 
(R03, R05, and R07) had signs of limping/uneasiness in walking gait during the first week only. 
Three times a week, the rats were monitored for general mobility, specific mobility of hind legs, 
response to touch and signs of inflammation at the surgical area. No adverse events were 
observed and all the rats progressed at a healthy rate during the entire period of 8 weeks. 
 
Morphological analysis of the retrieved implants 
At 8 weeks, the rats were euthanized by controlled exposure to CO2 that was approved by the 
IACUC protocol. After the joint retrieval, the knees were scored blindly by three independent co-
authors. The scoring was carried out for macroscopic observations based on the presence of 
repair tissue, presence, edge integration at the boundaries of newly regenerated tissue and the 
native cartilage, smoothness of the repair surface, degree of filling at the cartilage surface, color 







criteria were developed as a modification from the ICRS scoring chart, represented in Table 6.2. 
249
 The joints were photographed and processed for histology. 
Histological preparation and staining 
At 8 weeks, rat knees were retrieved and immediately placed in 10% neutral buffered formalin 
(Fisher Scientific, Rockville, NJ) for 72 hours, changed every 24 hours. After fixation, the joints 
were rinsed in distilled water and decalcified (Cal Rite, Richard-Allan Scientific, Kalamazoo, 
MI) for 2 weeks and the solution was changed every 3 days. After decalcification, the knees were 
rinsed briefly and dehydrated in graded ethanol. For paraffin embedding, the samples were 
cleared with xylene and then infiltrated with paraffin and the infiltrate was changed every 3 
hours. After three infiltrations, the trochlear grooves were embedded in paraffin tissue cassettes 
and allowed to cool down before sectioning. Sagittal sections were taken on a microtome 
(Thermo Scientific; Microm HM 355S) using a tungsten carbide blade with a sample thickness 
of 7 μm, and placed on coated glass slides (Superfrost coated slides, Thermo Scientific, NJ) and 
dried for 24 hours at 44°C. The glass slides were cleared in xylene and slowly hydrated in series 
of ethanol according to a procedure previously reported 
73
. After incubating the slides in ddH2O 
for 5 minutes, the slides were stained with either Safranin-O/Fast green stain for 
glycosaminoglycans (GAGs) or hematoxylin and eosin to look at overall structure. Slides were 
briefly dehydrated and cleared in xylene for mounting. Furthermore, additional slides were 
processed for immunohistochemistry (collagen I, II, and aggrecan) discussed in the next section. 









The slides were processed similar to basic histology as described above up through hydration in 
distilled water. The sections were then exposed to 3% hydrogen peroxide in methanol for 10 
minutes to suppress endogenous peroxidase activity, and the slides were immediately incubated 
in proteinase K (IHCWORLD IW-1101, Woodstock, MD) at 37C for 10 minutes. Sections were 
blocked with 3% blocking horse serum (Vector Laboratories S-2012, Burlingame, CA) for 30 
minutes preceding primary antibody incubation. The list of primary antibodies, corresponding 
dilution and vendor information can be found in Table 6.1. Following primary antibody 
incubation, slides were exposed to biotinylated secondary antibody (horse anti-rabbit IgG) and 
ABC reagent (Vectastain ABC kit PK-6200, Burlingame, CA) for 30 minutes each. Visualization 
was accomplished with ImmPact DAB peroxidase substrate (Vector laboratories SK-4105, 
Burlingame, CA) before rinsing with distilled water and counter stained with VECTOR 
hematoxylin QS stain. Following staining, slides were rinsed in tap water; dehydrated in ethanol, 
cleared in xylene for mounting (Permount SP15-500 Fair Lawn, NJ), and viewed under an 
upright microscope (Zeiss, Axiomanager 2.0, Thornswood, NY). Negative controls for IHC 
consisted of isotype IgG controls (Life Technologies) being added instead of the primary 
antibody. 
Histology scoring 
A simple scoring system (Table 6.3) was modified from the previously reported system of 
O’Driscoll et al.
197







observers performed all scoring and the assignment of the scores was aided by evaluating 
structure using histological and immunohistological images.  
Statistical analyses 
Wherever applicable, all data are expressed as mean ± standard deviation. Statistical analyses 
were performed using one-way ANOVA (Minitab 15, Minitab Incorporated, State College, PA), 
followed by a Tukey’s post hoc comparison test for repeated measurements. The statistical 
significance threshold was set at 0.05 for all tests (with p < 0.05). 
 
RESULTS 
Gross morphological observations 
All of the rats continued to exhibit normal movement and gait in their hind legs during the 8 
week period (other than noted exception in the Methods of three rats during the first week). 
Gross signs of inflammation (swelling or reddening of the joint) or infection were not evident 
upon visual inspection of the joint surface at the time of tissue retrieval. Figure 6.3 shows 
representative gross morphology images of the rat trochlear grooves at 8 weeks. The highest, 
intermediate and lowest scoring samples are shown for each group. For Group B, the repair 
tissue was completely flush to the surface and had a smooth texture surrounding the defect area 
with color similar to the native cartilage, whereas all of the other groups had an opaque, slightly 
depressed or overgrown surface with either rough or intermediate texture at 8 weeks. Figure 4a 
represents the mean morphological score and Figure 4b represents the percent area occupied by 







each sample at 8 weeks. The percent area values were between 80%-95% for Group A and the 
sham and fibrin groups. Group B values were between 95%-100%. Group B received a 1.35-fold 
higher morphological score (Figure 4b) than Group A alone (p < 0.05). Group B did not have a 
statistically significantly higher score compared to sham and fibrin groups. The difference in 
mean morphological score between Group A and fibrin group and sham group was not 
statistically significant.  
 
Histomorphometric observations 
Figure 6.5 shows representative sections stained with H&E, Safranin O for GAGs, Collagen I, II, 
and aggrecan immunostaining, for Group A. Rat #2 (i.e., R02) (Fig. 6.2) had intense Saf-O 
staining, whereas R04 and R09 did not stain very intensely. Figure 6.6b represents the 
morphometric score distribution of Saf-O stained sections of the defect area, and we observed 
that 40% of the knees were slightly stained, 20% were moderately stained and the remaining 
40% was normally stained. Collagen II staining was prominent in the defect region for R03 and 
R04, and aggrecan immunostaining was intense for R04 and R09 cartilage region. There was no 
intense staining of collagen I around the defect area, but overall there was a mild staining 
throughout the subchondral bone region. 60% of Group A knees received a score of 2 (75%-
100% of adjacent cartilage) and the remaining 40% received a score of 3 (100% thickness of the 
adjacent cartilage) (Figure 6.6a). Additionally, 60% of the Group A knees showed normal 
subchondral bone regeneration with smooth and intact edge integration of the defect with the 
surrounding native cartilage. Upon closer observation at the defect region, Group A aggregates 
(R01 and R04) showed columnar arrangement and are surrounded by tiny lacunae spaces. The 







collagen II and aggrecan pericellular staining. Apart from R02, there was no presence of cellular 
clusters in any of the Group A defects. There were small aggregates at the defect site, but it was 
not possible to say whether they were the implanted rBMSC aggregates or host-cell aggregates. 
 
Figure 6.7 displays representative sections stained with H&E, Saf-O for GAGs, Collagen I, II, 
and aggrecan immunostaining for Group B. R06 and R08 sections did not display any Saf-O 
staining, but intense staining for R07 and staining around the defect area for R05. 60% of the 
samples had a Saf-O score of 1 (slight staining) and the remaining 40% a score of 3 (nearly 
normal staining) (Figure 6.6a). Collagen II staining was intense in the defect area for R06 and 
R08, and aggrecan staining was evident in the defect region for R05, R07, and especially R06. 
Collagen I staining on the other hand was intense only for R06 in the defect area. As indicated by 
Fig. 6, 80% of the knees exhibited 75%-100% cartilage thickness and reduced subchondral bone 
reduction. 60% of the knees had a smooth and intact edge integration of the regenerated cartilage 
with the surrounding tissue. Looking at the cellular appearance in Group B defects, we observed 
that none of the regenerated tissue showed a columnar arrangement. There were no distinct 
lacunae observed except for R05 and R08, where the lacunae spaces increased at the 
osteochondral junction. R06 showed intense collagen II and aggrecan pericellular staining.  For 
R06, the cells in the defect region had a more intense pericellular collagen I and II staining 
compared to the surrounding tissue. H&E and Saf-O staining of R07 revealed aggregates at the 
osteochondral interface. In general, the cell aggregates appeared to be dispersed throughout the 








Figure 6.8 shows representative sections stained with H&E, Saf-O for GAGs, Collagen I, II, and 
aggrecan immunostaining, for the fibrin-only group. Saf-O staining was prevalent in the defect 
area for R07 and R09. The staining for Saf-O for the native tissue was evident for R02 and R05. 
80% of the fibrin group showed moderate staining to Saf-O (Fig. 6.6). Collagen II 
immunostaining was dense for R09 and R05, whereas aggrecan immunostaining was intense on 
the surface of the defect area for R03, R05, R07, and R09. Collagen I staining was intense in the 
defect area for R05 and stained deeper in the bone defect region for R02 and R03. 100% 
cartilage thickness was observed in 60% of the knees. Just like the sham defect group, 80% of 
the samples had reduced subchondral bone regeneration and only 60% showed superficial 
horizontal lamination. The regenerated tissue of the fibrin group did not show any columnar 
organization of cells. The cells in R05 and R10 sections showed lacunae-like appearance. R10 
showed intense collagen II and aggrecan pericellular staining. The cells in the regenerated tissue 
for R07 showed intense collagen I staining compared to the surrounding cartilage tissue and 
similarly the defect area tissue had increased aggrecan around the cells compared to the 
surrounding tissue. In general, there was no appearance of cell clusters in any of the images. 
 
Figure 6.9 displays representative sections stained with H&E, Saf-O for GAGs, Collagen I, II, 
and aggrecan immunostaining, for the sham knee surgeries. R01 demonstrated distributed Saf-O 
staining, but the regenerated tissue looked weak with a visible fissure in the bone-cartilage 







on the other hand had Saf-O staining at the regenerated cartilage surface. As indicated by the 
morphometric analysis, 80% of the group had moderate Saf-O staining and the remaining 20% 
had regular Saf-O staining, comparable to that of native cartilage (Fig. 6.6). Collagen II staining 
was evident for the regenerated surface for R01, R08 and R10, and aggrecan immunostaining 
was intense for R08 and R10. Collagen I was not evident for any other group except R08. 40% of 
the samples showed 100% of normal cartilage thickness and the remaining 60% had 50%-75% of 
native tissue thickness (Fig. 6.6). 80% of the samples had reduced subchondral bone regeneration 
and the remaining 20% showed normal bone regeneration without any sclerosis or loss of bone 
tissue. As far as edge integration with the native tissue was concerned, 60% showed superficial 
horizontal lamination and 40% showed smooth and intact integration. The regenerated tissue of 
the sham group did not show any columnar organization. There were no lacunae present in any 
of the sections. Only R01 and R04 sections displayed intense collagen II pericellular staining. 
Only R04 showed intense aggrecan staining of cells in the defect area compared to the 
surrounding tissue. There were no cell clusters in any of the images.   
 
DISCUSSION 
In the current pilot study, we have introduced for the first time a new method to incorporate 
cellular aggregates into an animal model as a proof of concept study. The rat trochlear groove is 
an established animal model that provided a great insight into both the potential and limitations 










As noted at 8 weeks, the fibrin-only control group demonstrated extensive tissue regeneration, 
marked by full thickness tissue, presence of GAGs, dense collagen II and aggrecan 
immunostaining. In the experimental groups, Group B had the highest average morphological 
score and highest percentage filling of the defect area compared to all other groups. From the 
data presented here, there is evidence that dense rBMSC aggregates (Group B) may be beneficial 
for osteochondral tissue engineering. Notably, the current immunohistochemistry analyses 
showed localized pericellular staining of collagen II and aggrecan in the Group B implants that 
was observed for only one section in the sham surgeries. 
 
A potential limitation with respect to use of rat trochlear grooves for a cartilage regeneration 
study is that the negative control group may not be ideal. A primary observation was the 
spontaneous healing of all of the sham groups. Previous studies by other groups that had looked 
at sham surgeries in the rodent trochlear groove region (rat and rabbit) had also observed that this 
may be a common trend for a typical small animal model.
41, 220
 Additionally, in the current study 
made sure the starting weight of the rats were comparable, however the variation in age of the rat 
might contribute toward a slightly different result owing to different regeneration rates of both 
the sham and the experimental group. 
 
The trochlear groove in a lower weight bearing region is considered an appropriate model for 
proof of concept studies.
124, 194
 Upon incumbent success of cartilage regeneration in the groove 







iteration of studies on a true load-bearing defect site in a large animal model to show more 
pronounced differences in regeneration between sham and experimental groups. 
 
Earlier studies that employed biomaterials on rat trochlear groove regeneration for critical sized 
defects have shown similar rates of regeneration.
55, 113
 Although previous rat studies have not 
explicitly provided aggrecan immunohistochemistry, based on morphological scoring and basic 
histology (H&E, Saf-O), similar rates of regeneration may be inferred.
47, 143
 Although there were 
minor variations in the time period of study and differences in evaluation method, basic 
histology and morphology scores reveal the parameters associated with determining the 
technology feasibility. Munirah et al.
188
 have demonstrated that fibrin mixed with autologous 
cells resulted in osteochondral regeneration in a sheep model. Similarly, Deponti et al.
62
 
demonstrated that fibrin mixed with porcine cells possessed enhanced in vivo properties 
compared to in vitro conditions, for increased cell viability and activity.  
Overall, the current study adequately established proof of concept. The cellular aggregates did 
not necessarily demonstrate conclusive outperformance of the fibrin group. The results of the 
current study, with differences between Groups A and B, suggested that there may be more 
effective ways to combine fibrin with cell aggregates. For example, exploring different cell 
densities for the aggregates, larger numbers of aggregates, aggregates of other cell types (e.g., 
Wharton’s jelly cells
63, 256, 259
), pre-treatment of aggregates, or differences in surgical placement 
procedure may be warranted for future investigation in an attempt to more conclusively prove the 
hypothesis that aggregates provide superior and more consistent cartilage regeneration compared 








Now that the feasibility and the potential of the aggregate technology has been demonstrated, 
experimental designs will be expanded in future studies to include larger defect sizes, bigger 
animal models, larger aggregate sizes, higher aggregate numbers and cell density of the 
aggregates and more sophisticated techniques to differentiate between the implanted and host 
cells even after several months of implantation. From a clinical standpoint, comparison of cell 
suspensions with fibrin versus cell aggregates with fibrin would yield meaningful and a more 
direct implication of the efficacy of aggregate technology over conventional cell suspension 
techniques. Furthermore, aggregate technology may augment current existing methods such 
autologous chondrocyte implantation (ACI) to produce a new class of products for treating focal 
cartilage lesions. The current study has clearly established a proof of concept for a novel 
approach of incorporating aggregates of rBMSCs with two different cell densities for 
osteochondral defect repair. 
 
CONCLUSIONS 
The current study demonstrated a cell-based approach where stem cell aggregates employed with 
fibrin were used for regenerating the osteochondral interface tissue in a rat knee defect model. 
This is the first in vivo study that employed dense cellular aggregates in a trochlear knee defect 









In conclusion, the inclusion of fibrin showed some degree of regeneration that may have been 
enhanced with the higher aggregate density group. Between the two experimental groups, the 
higher cell density aggregate group (Group B) demonstrated superior cartilage regeneration 
compared to all other groups and arguably had the most complete defect filling. The complete 
filling was believed to be the result of denser cellular aggregates in Group B that enabled better 
cell-to-cell interaction and filled the defect and remained intact due to its relative density. The 
merit of the study design shows potential in that the cellular density of the aggregates is an 
important parameter in osteochondral tissue regeneration, which may further be facilitated by the 
priming of rBMSC aggregates and exploration of even higher cell densities or larger numbers of 








CHAPTER 7: Conclusion 
 
Microsphere-based scaffolds for osteochondral tissue engineering represent a well-
established research direction in my advisor’s laboratory. The encapsulation of raw materials in 
scaffolds has several pressing benefits when cells were seeded on these polymeric scaffolds. The 
individual properties of the acellular scaffolds, however, were not clearly established.  I started 
my thesis by fabricating and characterizing CS and TCP encapsulated microsphere-based 
scaffolds, by evaluating the dry weight, molecular weight, mechanical properties, and bioactive 
factor (CS and TCP) retention in these scaffolds over a period of four weeks. Next, the focus 
shifted entirely to testing the feasibility of stem cell aggregates encapsulated in a hydrogel 
system and to further refining the aggregates by priming them under different medium 
compositions and substrate stiffness. Lastly, the in vivo potential of the aggregates was tested in 
a rat knee cartilage defect model. All of these projects have assimilated substantial knowledge in 
the field of stem cell aggregates for osteochondral applications. 
  Bone marrow mesenchymal stromal cells (BMSC) are the most investigated MSC for 
tissue engineering applications and are considered the “gold standard” cell source in 
musculoskeletal tissue engineering. BMSCs provide an autologous cell source for tissue 
engineers to avoid potential immune rejection. However, there are some limitations to the 
applications of BMSCs, including the low number of BMSCs in marrow, their proliferation 
ability and the fact that their differentiation potential decreases significantly with age. Moreover, 
the invasive harvesting procedure may lead to complications and morbidity. Financially, the 
biopsy of the marrow fluid only adds extra cost to the overall healthcare, thus rendering it less 







obtained from stroma of the discarded human umbilical cord. Human umbilical cord 
mesenchymal stromal cells are a multipotent stromal cell population that are plastic adherent, 
share MSC surface markers such as CD73, CD90 and CD105, and are non-hematopoietic cells. 
The cells represent a steady and sustainable source of cells and do not have any donor site 
morbidity issues.  
Different sources of stem cells have varied potential in generating neo-cartilage tissue under 
a given set of conditions. Two of the main challenges of using BMSCs are the number of cells 
that can be isolated from a single biopsy, and donor site morbidity. However, hWJC isolation 
does not suffer any morbidity issues and can be obtained without an extra surgery, thereby 
saving healthcare cost. Due to variations between donors, it is eminent to establish quality 
control and prescreen cells and look for presence of certain surface markers that can then be 
“approved” as viable hWJC for transplantation. The next important consideration is the delivery 
of spheroids in a user-friendly manner, so that the end-user, in this case surgeons, can 
incorporate the spheroids into the defect area without a significant hassle. There are many ways 
to go about this idea. Currently, the spheroids are only considered for focal defects that are 
defined as cartilage defects less 2 cm
2
 in area. For such defects, a pre-made solution of 
fibrinogen with encapsulated spheroids can be delivered in a tight and sterile syringe on the day 
of the surgery through local-delivery centers. The spheroids would be suspended in a paste-like 
solution until further use. Upon injection into the defect site, the fibrinogen would clot in the 
presence of blood to ensure tight adherence of spheroids within the defect region. However, for 
such controlled procedures, logistics would play a key role in both the starting stages (collection 







In an attempt to explore the advantages of stem cell aggregates, rBMSC and hWJC 
aggregates were fabricated under two different cell densities. When encapsulated in an 
agarose hydrogel model and testing against cellular suspensions, results indicated that on a 
per cell basis, the high cell density aggregates outperformed cell suspensions in terms of 
biochemical analysis and gene expression data. Furthermore, the number of cells per 
aggregate played an important role in determining the initial performance of the 
aggregates, with high cell density aggregates (20,000 cells per aggregate) outperforming 
the low cell density aggregates at initial time points. However, since it was a proof of 
concept study, the experiment was only conducted for 3 weeks. The limitation of this study 
design was employing a relatively inert polymer such as agarose. Agarose was selected as a 
proof of concept model, and upcoming studies would benefit from employing a bioactive 
material; like hyaluronic acid and poly ethylene glycol. Although the Picogreen assay 
measures the DNA content, it provides no information on the actual number of live cells.  
 Similarly, the live-dead assay overall demonstrated that in some cases the aggregate 
stained only around the edges and staining at the center was not visible.  This “Rim Effect” was 
observed in denser aggregates possibly due to diffusion limitations of the dye. The phase contrast 
image below showed that there were cells in the center of the aggregate but did not stain mainly 
due to the diffusion limitation imposed by the dense cellular structure. 
 To verify better viability, metabolic indicator assays that can be employed for future 
studies fall under indicator dyes (MTT/MTS/Resazurin), protease marker and ATP. The most 
commonly employed Resazurin dye based assay works under the principle of NADH (present in 







products. Another assay works by measuring the aminopeptidase activity that is present only in 
viable cells, using a permeable fluorogenic substrate. Finally, ATP present in viable cells can 
also be measured using a beetle luciferase reaction to generate light. 
Detailed protocols on immunocytochemistry on hydrogels might also shed light on basic 
differentiation pathways. Evaluation over a period of 6 weeks or longer would yield valuable 
information on long-term evaluation of aggregates and the influence of cell density and 
aggregate number. 
Next, the roles of surface stiffness and media composition of the rBMSC aggregates were 
tested. Results suggested that while growth factor primed media (IGF) may have outperformed 
other groups in terms of SOX-9 gene expression, raw material (CS and aggrecan) primed media 
demonstrated higher GAG and collagen content per DNA, compared to all of the other groups. 
The results suggested that raw materials incorporated in the medium might be a new way to look 
at medium formulations and might have comparable therapeutic properties to those offered by 
growth factors. In the future, methods to quantify surface stiffness and cellular interaction on the 
surface may add more insight into understanding the role of surfaces. As enlisted above, cell 
aggregates are neither considered cells nor a developed tissue and hence falls midway for 
histology processing. Dedicated aggregate immunohistochemistry protocol development would 
yield useful information on the aggregate architecture and morphology. Future studies may 
consider coating well plates with different materials and optimize the coating efficiency of 
surfaces to ensure sustenance. The other useful information to gather would be the analysis of 








In vivo, higher cell density aggregates outperformed the low cell density aggregates 
and the control groups in terms of morphological scoring and defect filling. Thickness was 
measured by averaging values from three different points, two on the periphery of the defect and 
one from the center. This measurement was repeated for all of the samples for all of the groups 
(n = 5). Similarly, the ratio of defect thickness by healthy cartilage was calculated by measuring 
of the deepest point in the defect divided by the value of adjacent healthy cartilage thickness. 
The thickness ratio calculation was again repeated for all of the groups (n = 5).  
Additionally, the aggrecan and collagen II staining was intense in higher cell density 
aggregates and fibrin groups, compared to the low cell density and sham surgeries. What the 
study sorely missed was assessing the mechanical properties of the rat knees. With the help of 
proper equipment and expertise, the addition of mechanical testing analysis would help provide a 
more complete picture. The future experiments can take into consideration a greater weight-
bearing region and a larger animal such as rabbit or sheep. Additionally, cell-based in vivo 
studies would benefit from efficient fluorescent labeling of the implanted cells, to accurately 
determine the contributions of individual groups in the regenerated cartilage. 
Overall, the results of the in vivo study were instrumental in establishing the feasibility of 
using stem cell aggregates and helped in setting the stage for future animal experiments, and the 
next set of in vitro studies to refine and enhance the chondrogenic performance of the aggregates. 
As a future recommendation, using genetically modified stem cells expressing stable GFP/LacZ 
reporter gene that are developed using recombinant viral vectors to get stable expression could 







Cell aggregates have been utilized for a myriad of applications such as pancreatic islet 
cell clusters, spheroids for cancer drug testing, and embryonic aggregates for organ regeneration. 
The versatile nature of the 3D stem cell aggregates lends itself to be applicable to almost any 
kind of organ engineering, when presented with the right orchestration of micro-environmental 
cues. With so many promising applications outside of the osteochondral field, this thesis presents 
as a first serious attempt at turning the direction toward the articular cartilage phenotype. With 
the evidence presented within this thesis, it is apparent that the approach of using stem cell 
aggregates for cartilage regeneration is entirely feasible, and in many instances, efficacious.  
Within four years, stem cell aggregates have been taken from conception to practice, and 
has also produced encouraging in vivo data for osteochondral regeneration. Throughout the 
process of iterations and refining, aggregates have produced several exciting ideas to consider 
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Figure 2.1: Translation of devices and stem cell products for cartilage regeneration 
Translation of devices and stem cell products for cartilage regeneration (from Lee et 
al.
144
) (A) FDA regulation of biologics requires stem cell products to exhibit purity, 
reproducibility, and stability. Neocartilage is evaluated in preclinical trials for 
biological response, durability, toxicology, and dose response. Multi-phase clinical 
studies are used to evaluate dosage, efficacy, and safety. (B) Two major regulatory 
centers exist: CDRH for devices and CBER for drugs and biologics. Prior to initiating 
clinical trials, a product must receive an IDE or IND. After clinical trials, market 





















Figure 3.1: SEM micrographs of the different groups 
SEM micrographs of scaffold taken at weeks 1, 2, 3 and 4. In general, PLGA 50:50 
(CS control) degraded faster than PLGA 75:25 and the CS group microspheres 
displayed interconnected pores and large cracks right from week 1. TCP group 























Figure 3.2: Dry weight and molecular weight of the scaffolds 
Dry weight and molecular weight analysis of the scaffolds. (a) Relative dry mass 
(n=5), of all the groups over a 4 week period, (b) weight-average molecular weight 
change Mw (n=4), of polymeric scaffolds in the aqueous medium over time. Raw 
materials (CS & TCP) encapsulation led to faster decrease in Mw than the control 
groups. All groups exhibited more than 10% decrease in Mw by the end of week 4. (*) 























Figure 3.3: CS and TCP retention in scaffolds 
Retention of (a) CS and (b) TCP, in the CS group and TCP group scaffolds, 
respectively (n = 5). The CS microsphere-based scaffolds degraded at a much faster 
than the TCP group microspheres. Error bars represent mean ± SD. (*) denotes 






















Figure 3.4: Compressive elastic moduli at different time points 
Compressive elastic modulus at different time points. CS group scaffolds lost shape 
by week 3 and hence there was no solid material for measurement at week 3 and 
week 4. (*) indicates statistically significant difference (p < 0.05) from week 0. (**) 
indicates statistically significant difference (p < 0.05) from the corresponding control 
group. (#) indicates statistically significant highest value of the parameter (p< 0.05) 







Figure 4.1: Schematic representation of the hanging drop approach 
Schematic representation of the hanging down approach and aggregate-encapsulation 
in agarose hydrogels. The aggregates/CS is encapsulated in pre-polymer solution and 






List of analyses 
• Cell viability 
• Biochemical assay (Collagen, GAG, DNA content) 
• IHC (Aggrecan, Collagen I, II) 
• PCR (Aggrecan, SOX9, Collagen I, Runx 2) 
Agarose hydrogels with 
aggregates 
Agarose hydrogels 
with cell suspension 
 
Hanging drop technique  




Biochemical assays (collagen, GAG, DNA content) 
IHC (aggrecan, collagen I, II) 





















Figure 4.2: Cell viability of the rBMSC aggregates 
Cell viability at weeks 0 and 3. (A) Live-dead images of the 10M/mL rBMSC 
aggregates and controls. (B) Live-dead images of the 20M/mL rBMSC aggregates 



























Figure 4.3: Cell viability of the hWJC aggregates 
Cell viability at weeks 0 and 3. (A) Live-dead images of the 10M/mL hWJC 
aggregates and controls. (B) Live dead images of the 20M/mL hWJC aggregates. 
















Figure 5.4: Cell viability of the hWJC aggregates 
Cell viability at weeks 0 and 3. (A) Live-dead images of the 10M/mL hWJC 
aggregates and controls. (B) Live dead images of the 20M/mL hWJC aggregates. 









Figure 4.4: DNA content for all of the groups  
DNA content for all the rBMSC and hWJC groups at 0, 2, and 3 weeks expressed as 
DNA (g/ scaffold). (A) DNA content of all the rBMSC LA and LA CS groups. (B) 
DNA content of all the rBMSC HA and HA CS groups. (C) DNA content of all the 
hWJC LA and LA CS groups. (D) DNA content of all the hWJC HA and HA CS 
groups. All aggregate groups had statistically significant increase in DNA over week 
0, HA groups had significantly higher values compared to the CS control groups at 
week 3. Values are reported as mean  standard deviation, n=4. (*) represents 
statistically significant difference from the week 0 value. (#) represents statistically 
significant difference from the previous time point and (**) represents statistically 




















Figure 4.5: GAG content for all of the groups 
GAG content for all the rBMSC groups at 0, 2, and 3 weeks expressed as GAG/DNA 
(A&B). All aggregate groups had statistically significant increase in GAG/DNA over 
week 0, and select aggregates groups had significantly higher values compared to the 
control groups at week 3. GAG content for all the hWJC groups at week expressed as 
GAG/ DNA (C&D) at week 0, 2, and 3. 10 M HA at week 2 exhibited the highest 
GAG/DNA value and decreased at week 3. Values are reported as mean  standard 
deviation, n=4. (*) represents statistically significant difference from the week 0 
value. (#) represents statistically significant difference from the previous time point 
and (**) represents statistically significant difference from the control at that time 





















Figure 4.6: Collagen content for all of the groups 
Collagen content for all the rBMSC groups expressed as collagen/DNA (A&B) at 
week 0, 2, and 3. All aggregate groups had statistically significant increase in 
collagen over week 0. At week 3, 20 M HA also displayed the highest collagen/DNA. 
Collagen content for all the hWJC groups expressed as collagen/DNA (C&D) at week 
0, 2, and 3. We noticed that the 20 M HA at week 0 had the highest collagen/DNA 
value. Values are reported as mean  standard deviation, n=4. (*) represents 
statistically significant difference over the week 0 value. (#) represents statistically 
significant highest value of the particular group and (**) represents statistically 













Figure 4.7: Gene expression for all of the rBMSC groups 
Gene expression of Collagen I, Aggrecan and SOX9 for rBMSC groups at week 0, 2, 
and 3. There was significant increase in the SOX9 and Aggrecan value at week 2 and 
3 for 20 M HA group, compared to the controls. Values are reported as mean  
standard deviation, n=4. (*) represents statistically significant difference over the 
week 0 value. (#) represents statistically significant highest value of the group (**) 































Figure 4.8: Gene expression for all of the hWJC groups 
Gene expression of Collagen I, Aggrecan and SOX9 for hWJC groups at week 0, 2, 
and 3. There was significant difference in SOX9 and Aggrecan gene expression at 
week  by groups @)M HA and 20 M HA CS groups. Values are reported as mean  
standard deviation, n=4. (*) represents statistically significant difference over the 
week 0 value. (#) represents statistically significant highest value of the group (**) 









































Figure 4.9: Immunohistochemistry for all of the rBMSC groups 
 
Representative images for immunohistochemistry analysis for collagen I, collagen II, 
and aggrecan staining for rBMSC groups at weeks 0, 2, and 3. At week 2, 20M LA 
had the most intense staining for collagen II and aggrecan. At week 3, 10M LA had 










































Figure 4.10: Immunohistochemistry for all of the hWJC groups 
 
Representative images for immunohistochemistry analysis for collagen I, collagen II, 
and aggrecan staining for hWJC groups at weeks 0, 2, and 3. At week 2, 20M LA had 
the most intense staining for collagen II and aggrecan. At week 3, 10M LA had the 







Figure 5.1: Schematic representation of the experimental design 
 
rBMSCs were aggregated via the hanging drop technique and harvested after 24 h. 
Subsequently, aggregates were plated onto HA-coated 96 well plates and cultured for 
0 and 7 days. The individual aggregates were subjected to five different culture 
medium conditions, namely Dulbecco’s modified eagle medium (DMEM) with (a) 5 
ng/mL TGF-β3, (b) 100 ng/mL IGF, (c) 40 μg/mL of porcine chondroitin sulfate (d) 

































Figure 5.2: Live-dead images for all the different time points 
 
Live/dead images demonstrating cell viability at different time points (a) rBMSC 
group before aggregate formation, (b) rBMSC aggregates 24 h after hanging drop, (c) 
24 h after aggregates were placed in HA coated substrates and 7 days after they are 



































Figure 5.3: DNA content for all of the groups 
 
DNA content analysis of the different groups using the picogreen assay measured at 0 
and 7 days. Please note the decrease in DNA content for all of the groups after 7 days 
of culture. Values are reported as mean  standard deviation, n=4. (*) represents 































Figure 5.4: Normalized GAG content for all of the groups 
 
Normalized GAG content measured at 0, and 7 days, expressed as GAG/DNA. The 
IGF group had the highest GAG/DNA content at 7 days non-coated time point. 
Values are reported as mean  standard deviation, n = 4. (@) represents statistically 
significant difference from the control group at that time point and (*) represents 































Figure 5.5: Normalized collagen content for all of the groups 
 
 Normalized collagen content measured at 0 , 7 and 14 days, expressed as 
collagen/DNA. The IGF group at 7 days non-coated time point, had the highest 
collagen/DNA content. Values are reported as mean  standard deviation, n = 4. (@) 
represents statistically significant difference from the control group at that time point 





































Figure 5.6: Gene expression for all of the groups 
 
Gene expression  of Aggrecan, SOX9, collagen I, and collagen II. While aggrecan 
gene expression was enhanced for hanging drop group, the collagen II and SOX9 
gene expression was highest at the 7 day coated/non-coated group. Values are 
reported as mean  standard deviation, n = 4. (*) represents statistically significant 
difference over the week 0 value, (@) represents statistically significant difference 
from the control group at that time point and (*) represents statistically significant 





































              
 
 
Figure 5.7: Immunohistochemistry for all the rBMSC groups 
 
Representative images for immunohistochemistry analysis for collagen II, collagen I, 








































Figure 6.1: Schematic representation of the surgical procedure 
 
After defect creation with a drill bit, the rat knees were subjected to one of four 
treatments. Group A and Group B refer to the 10 million/mL and 20 million/mL 
aggregates, respectively. After aggregates were added in the defect area, 50 μL of 
fibrin sealant (Tisseel ®) was additionally added as a topmost layer to form a secured 
clot. Sham refers to an empty defect without any filling and fibrin Group refers to 






































Figure 6.2: Experimental design and surgery photos 
 
Overall experimental design and photos of the rat trochlear groove, before and after 
aggregate filling. Note n = 5 knees for each Group. To maintain independence of 
samples within groups, each individual rat received a different group for the left and 



































Figure 6.3: Gross morphological images of the different groups 
 
 Representative gross morphological images of all the experimental and control 
Groups. They are divided into three categories based on the relative morphological 
appearance. The repair tissue was opaque, almost flush to the surface and had smooth 
or intermediate texture in Group B implants, whereas all of the other groups had 
opaque, slightly depressed or overgrown surface, with either a rough or intermediate 
texture at 8 weeks. (Circled region points to the defect area on the trochlear groove on 

































Figure 6.4: Morphological assessment of the rat knees 
 
(a) Average morphological score of the rat knees. (b) percentage of repair tissue filled 
at the defect site in for all the groups. Three independent co-authors compiled 
morphological scores based on parameters in Table 6.2. Average scores are 
represented as mean + standard deviation. The maximum possible score a healthy 
cartilage can receive is 10. All groups had a sample size of n=5. (*) indicates 
































Figure 6.5: Histology and IHC for Group A implants 
 
Histology (H&E, Saf-O) and immunohistochemistry (collagen I, II, and, aggrecan 
antibody staining) for Group A. Black arrowheads indicate defect region. Numbers on 
the top refer to the rat number (see Fig. 2). Note that the aggrecan and collagen II 







































Figure 6.6: Histological score distribution plots 
 
Stacked column plot showing the histological score distribution for (a) cartilage 
thickness, (b) Safranin O staining, (c) reconstruction of subchondral bone, and (d) 
edge integration for the newly regenerated tissue at the defect area for 8-week 
implants. The sections were scored using modified O’Driscoll score as shown in 







































Figure 6.7: Histology and IHC for Group B implants 
 
Histology (H&E, Saf-O) and immunohistochemistry (collagen I, II, and aggrecan 
antibody staining) for Group B. Black arrowheads indicate defect region. Numbers on 
the top refer to the rat number (see Fig. 2). Note the more intense stain for collagen II 






































Figure 6.8: Histology and IHC for Fibrin-alone implants 
 
Histology (H&E, Saf-O) and immunohistochemistry (collagen I, II, and aggrecan 
antibody staining) for the Fibrin group. Black arrowheads indicate defect region. 
Numbers on the top refer to the rat number (see Fig. 2). Note that the R05 section 
showed almost zero staining for Saf-O and the bone region for R09 was deeply 






































Figure 6.9: Histology and IHC for the sham surgeries 
 
Histology (H&E, Saf-O) and immunohistochemistry (collagen I, II, and, aggrecan 
antibody staining) for the sham Group. Black arrowheads indicate defect region. 
Numbers on the top refer to the rat number (see Fig. 2). Note that R01 has a deep 























Figure 6.10: Dual-beam microscopic image of the defect area 
 
 
(FEI Versa, 3D Dual beam, Hillsboro, OR) of rat #4 (R04) left knee (Group A). Scale 











APPENDIX B: Tables 
 
CHAPTER 1: No tables. 
CHAPTER 2: Tables 2.1 - 2.6 
CHAPTER 3: Table 3.1 
CHAPTER 4: Tables 4.1 - 4.2 
CHAPTER 5: Tables 5.1- 5.3 
CHAPTER 6: Table 6.1-6.4 










AC   Articular cartilage 
ACI   Autologous chondrocyte implantation 
ACL  Anterior cruciate ligament 
ASC/ADSC Adipose derived stem cells 
BMI  Body mass index 
DMEM Dulbecco’s modified eagle medium 
ECM  Extracellular matrix 
GMP  Good manufacturing practice 
HA   Hyaluronic acid  
IGF   Insulin-like growth factor 
IKDC   International knee documentation committee 
IND   Investigational new drug 
KOOS  Knee injury and osteoarthritis information store 
MRI   Magnetic resonance imaging 
MSC   Mesenchymal stem cells 
N/A  Not applicable 
NDA   New drug application 
OA   Osteoarthritis 
OATS  Osteochondral autograft transplantation procedure 
OCD  Osteochondritis dissecans 
PCL  Polycaprolactone 
PDS  Polydioxanone 
PEG  Poly(ethylene glycol) 
PEO  Polyethyleneoxide 
PGA  Polyglycolic acid 
PRF  Platelet rich fibrin 
PRP   Platelet rich plasma 
PLGA  Poly (L-lactic-co-glycolic-acid) 
SVF  Stromal vascular fraction 

















Technology overview Material composition Defect size Treatment condition 
Comparator 
group 
CAIS Canada 2 
Morselized autologus cartilage 
affixed on resorbable implant 
using fibrin sealant and implanted 
back into the knee 
Resorbable implant: 
copolymer of PGA & PCL 





dissecans and ICRS 





Bioceramic multilayer scaffold 
composed of deantogenated type 
1 equine collagen and magnesium 
enriched hydroxyapatite 
Chondral layer: 100% Type I 
Collagen, Tide-mark layer: 
60% collagen 40% HA, Bone 











HYTOP® is typically grafted with 
debridement or MF 
Upper layer of porcine splint 
skin and lower layer of 





1.1- 2 mm 











Cells implanted in a collagen 
scaffold are arthroscopically 
implanted 
6 million cells are implanted 
in a 10 mm collagen scaffold 
1.5-4 cm
2
 Focal chondral defects MF 
TruFit CB EU- mc 4 
TruFit CB plugs are implanted into 
defect regions 
TruFit CB:  resorbable 
material composed of PLG 
copolymer, calcium-sulfate, 









EU- mc 4 
Graft implanted perpendicular to 
defect site 
Cartilage phase: modified 
aragonite & HA, bone phase: 
aragonite 


















A miniarthrotomy is performed and 
after removal of defective 
cartilage, the cartilage pieces are 
implanted and held in place with 
fibrin sealant 
Viable juvenile cartilage 













Bone Graft Canada 
Pilot; 
0 
Chondral lesions are filled with 
Augment Bone Graft 
Material: matrix of beta 
tricalcium phosphate and 














Patients implanted with Chondron 
are analyzed to evaluate device 
performance 
Cell-gel mixture: autologus 
chondrocytes are mixed with 









BST-CarGel Canada NA 
Chitosan-based matrix which acts 
like a plug after the ACI procedure 
Cytocompatible liquid 










Table 2.3: List of biologic products under clinical trials for treating knee focal defects or 









































articular injection of 
MSC 
Osteoarthritis Placebo injection 
TissueGen
e Inc. 
TG-C USA 2 
MSC injections of 
different cell 
concentration 






















N/A Korea 1,2 
PRP injection, 
second injection 






group safety study) 
Stanford 
University 
ASC USA 1 
Fibrin glue, dermal 
















Autologus cells are 
isolated and mixed 
with patient's 









MSV   Spain 1,2 




Intra-articular injection of 






N/A Switzerland 1 
Nasal cartilage is 
isolated, grown on 
collagen type I/III 
membrane and 
implanted in knee 











9 PRP injections 
administered over 
a duration of 1 year 
Grade II or III 
chondromalacia 
None (open-label, single-
group safety study) 
Exactech, 
Inc 
BiCRI Taiwan 3 
1 or 2 scaffolds 







ISTO Inc Revaflex USA 3 
Decellularized neo-
cartilage scaffolds 























Neocart USA- mc 3 
ACI performed and 
cells are seeded on 
scaffolds and re-






















PRP Italy   
PRP versus 
viscosupplementati










N/A USA N/A 
ASC isolated from 
fat pad and injected 
into defect site 





































N/A India 2 
Ex- vivo cultured 
adult allogeneic 
MSCs 




































USA- mc N/A 
Impact of Stromal 
Vascular Fat on 
joint pain and 
functionality due to 
osteoarthritis 





Table 2.4: List of drug products under clinical trials for treating knee focal defects or 



















PRP UK NA 




















EU- mc 1 
AS902330 injection 
into knee defect 
Primary 
osteoarthritis of 
the knee and 
Kellgren-
Lawrence 










of  1 glucose injection 
at 1,2,3 months 








Jose E. Gonzalez 
PRP Mexico N/A 
PRP injection given 





















Blood, bone marrow 








Genzyme Synvisc USA 
Approve
d 
Hylan G-F 20 
(Synvisc) is an FDA-
approved hyaluronate 
derivative used to 





Novocart®3D Plus Tetec AG Germany 3 
Combination of 








The First Affiliated 






















solution delivered as 
an intra-articular 
injection for patients 
who have failed at 
















Table 2.5: Common inclusion and exclusion criteria to determine eligibility of the study 
cohort. The values are specific to osteoarthritis, focal lesions of the cartilage, osteoarthritis 
and osteochondritis dissecans disease pathology. (Source: clinicaltrials.gov) 
Common Inclusion Parameters: 
1. Age: Commonly 18-50 
2. Approved and signed IRB consent of the subject (includes ability to read, understand and write)  
3. Willingness to participate in post-op rehabilitation and clinical assays  
4. Normal BMI (≤ 35)  
5. Willingness to use more than 1 contraceptive device for childbearing aged women  
6. Clinically normal hematology and serum values 
7. Contralateral knee to be asymptomatic and functional  
8. Intact meniscus on both the knees  
9. Lesion region should be fillable by implant graft , if used 
10. Defect  grade: usually grade-III or grade- IV Kellergen Lawrence  
11. Defect dimension requirements (size, diameter and depth) corresponding to a particular study  





Common Exclusion Parameters: 
1. Pregnant or nursing women  
2. History of malignancy or exposure to radiation  
3. Autoimmune diseases (including rheumatoid arthritis) and immunocompromised patients  
4. Allergy to drugs such as penicillin, acetaminophen, aspirin, ibuprofen, gentamycin, streptomycin, 
polymyxin B sulfate  
5. Allergy to calcium phosphates, bovine serum or animal protein as described in the product 
6. BMI > 35  
7. Currently enrolled in other clinical studies  
8. Current or history of alcoholism and/or drug abuse  
9. Previous hyaluronic acid, PRP injection or microfracture technique.  
10. Abnormal level of liver enzymes, thyroid level, hepatitis and anti-coagulant therapy  
11. Hemoglobin level too low and a very low platelet count  
12. Undergone ACL in the last one year or rehabilitation in the last 6 months 
13. No history of knee fracture  
14. Patellofemoral instability  
15. Multiple or kissing lesions  
16. For treating lesions: patients must not have previous OA conditions  
17. Knee instability, bipolar articular cartilage defect, and axis alignment of tibial spines  
18. Anything that restricts MRI imaging (metallic implants or pacemakers in body, gadolinium 
allergy)  
19. Very high performance athletes who cannot ambulate for 20-30 minutes a day 




Table 2.6: Food and Drug Administration Approval Pathways for Cartilage Repair Products 










Center for Drug Evaluation 







Center for Devices and 









Center for Biologics 









Lead center determined after 













Group name Abbreviation Weight (per 100 g) 
1. 50:50 PLGA + CS + NaHCO3 CS group 77.5:20:2.5 
2. 50:50 PLGA CS control 100 
3. 75:25 PLGA + β-TCP TCP group 90:10 























rBMSC medium (αMEM with 
10% FBS) 
rBMSC 
TGF β3 (5 ng/mL) TGF 
IGF (100 ng/mL) IGF 
Aggrecan (40 μg/mL) Aggrecan 
Chondroitin sulfate (40 μg/mL) Chondroitin sulfate 
Spheroids in HA 
coated 96 well-
plate 
(i) 24 h after 
plating  (ii) 7 
days after 
plating 
rBMSC medium (αMEM with 
10% FBS) 
rBMSC 
TGF β3 (5 ng/mL) TGF 
IGF (100 ng/mL) IGF 
Aggrecan (40 μg/mL) Aggrecan 
Chondroitin sulfate (40 μg/mL) Chondroitin sulfate 
TGF β3 (5 ng/mL) for 3 days and 





7 days after 
plating 
rBMSC medium (αMEM with 
10% FBS) 
rBMSC 
TGF β3 (5 ng/mL) TGF 
IGF (100 ng/mL) IGF 
Aggrecan (40 μg/mL) Aggrecan 











Cell viability TGF β3, aggrecan Hanging drop 
DNA content rBMSC, IGF Hanging drop 
GAG/DNA content IGF 
7 days non-coated well 
plate 
Collagen/DNA content IGF 
7 days non-coated well 
plate 
Aggrecan gene expression Aggrecan Hanging drop 
SOX9 gene expression 
Chondroitin sulfate, 
TGF/IGF 
Hanging drop and 7 day 
HA-coated well plated 
Collagen I gene expression IGF 
7 day HA-coated well 
plated 
Collagen II gene expression Chondroitin sulfate 











Primary Antibody Dilution Vendor Catalog number 
Anti-collagen I, rabbit IgG polyclonal 1:200 Abcam AB24133 
Anti-collagen II, rabbit IgG polyclonal 1:200 Abcam AB116142 















Primary Antibody Dilution Vendor Catalog number 
Anti-collagen I, rabbit IgG polyclonal 1/200 Abcam AB24133 
Anti-collagen II, rabbit IgG polyclonal 1/200 Abcam AB116142 










Gross morphological parameter Scoring rubric 
Repair tissue Full=2, partial=1, none=0 
Edge integration Full=2, partial=1, none=0 
Smoothness of repair tissue 
Smooth=2, intermediate=1, 
rough/missing=0 
Surface degree of filling 
Flush=2, slight depression=1, 
depressed/overgrown=0 
Color of cartilage Opaque=2, translucent=1, missing=1 
Total morphological score Sum total of the above values 
Amount of repair tissue to total area 
(%) 
Amount of repair tissue relative to total 








Table 6.3: Histology scoring parameters and associated numeric score. The grading system 








Safranin O staining   




 Cartilage thickness   
100% of normal adjacent cartilage 3 
75%-100% of normal adjacent cartilage 2 
50%-75% of normal adjacent cartilage 1 
0%-50% of normal adjacent cartilage 0 
Reconstruction of subchondral bone 
Normal 3 
Reduced subchondral bone reconstruction 2 
Minimal subchondral bone reconstruction 1 
No subchondral bone reconstruction 0 
Edge integration   
Smooth and intact 3 
Superficial horizontal lamination 2 
Fissures 1 















Weight in grams (time 
of surgery) 
Weight in grams 
(time of death)  
R01 248 527 
R02 258 587 
R03 230 397 
R04 243 429 
R05 268 575 
R06 259 547 
R07 258 550 
R08 229 606 
R09 254 470 
R10 247 483 
 
 
